Cover Image
市場調查報告書

預填充式注射器的全球市場

Prefilled Syringes Market (4th Edition), 2017-2026

出版商 ROOTS ANALYSIS 商品編碼 283286
出版日期 內容資訊 英文 525 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
預填充式注射器的全球市場 Prefilled Syringes Market (4th Edition), 2017-2026
出版日期: 2017年01月06日 內容資訊: 英文 525 Pages
簡介

本報告提供預填充式注射器市場規模競爭分析,產品的基本概要,及各市場區隔趨勢等彙整資料。

第1章 序文

第2章 摘要整理

第3章 預填充式注射器的簡介

  • 本章概要
  • 預填充式注射器的歷史
  • 勝過傳統注射設備的預填充式注射器的優點
  • 預填充式注射器的零組件
  • 預填充式注射器的分類
  • 預填充式注射器設計重要的特性
  • 市售的預填充式注射器系統
  • 預填充式注射器的技術開發

第4章 針插事故

  • 本章概要
  • 事故與成本負擔
  • 預防針插事故的政府法案
  • 預填充式注射器廠商用的安全機制

第5章 預填充式注射器的法規情形

  • 本章概要
  • 美國
  • 歐洲
  • 加拿大
  • 巴西
  • 墨西哥
  • 阿根廷
  • 澳洲
  • 日本
  • 中國
  • 印度
  • 韓國
  • 沙烏地阿拉伯
  • 阿拉伯聯合大公國

第6章 促進成長要素

  • 本章概要
  • 自行注射患者數的增加
  • 慢性疾病發病率的增加
  • 患者統計的變化
  • 生技藥品、生技仿製藥的成長
  • 醫藥品策略的變化
  • 針插事故的防止對策的措施
  • 預填充式注射器和自動注射器/筆型注射器的整合

第7章 在預填充式注射器中可利用的產品

  • 本章概要
  • 已批准藥物
  • 已批准藥物:治療領域分析
  • 主要藥物
  • 其他藥劑
  • 案例研究
  • 開發平台中的藥物
  • 開發平台中的藥物:治療領域分析
  • 可利用的藥物:各治療層級

第8章 預填充式注射器藥物的候補

  • 本章概要
  • 已上市的分子
  • 開發平台中的分子
  • 疫苗

第9章 預填充式注射器的廠商

  • 本章概要
  • 北美的主要製造商
    • Becton Dickinson
    • Unilife Corporation
    • West Pharmaceutical Services
  • 歐洲的主要製造商
    • Aguettant
    • Gerresheimer
    • Nuova Ompi
    • SCHOTT
    • Vetter Pharma
  • 亞太地區的主要製造商
    • Nipro
    • Weigao Group Pharmaceutical Packaging Products Company
    • Terumo Corporation
  • 其他的廠商
    • Arte Corporation
    • J.O. Pharma (Subsidiary of Otsuka Holdings)
    • Roselabs Group
    • Shandong Zibo Minkang Pharmaceutical packing
    • Shandong Pharmaceutical Glass
    • 完成化工
    • Yangzhong Wealth Metal
    • Youlyy Industrial
  • 競爭情形的製圖

第10章 預填充式注射器零組件的廠商

  • 本章概要
  • West Pharmaceutical Services, Inc.
  • Datwyler
  • Aptar Stelmi

第11章 預填充式注射器的填充服務企業

  • 本章概要
  • 填充處理
  • 填充工作的外包
  • 成長相關討論事項
  • 填充服務企業
    • 北美
    • 南美
    • 歐洲
    • 亞太地區
    • 中東

第12章 特殊預填充式注射器

第13章 市場預測

  • 本章概要
  • 調查的範圍與手法
  • 全球市場的規模與預測
  • 各地區的市場預測
  • 各材料類型的市場預測
  • 各分子的市場預測

第14章 案例研究:自動注射器

第15章 近幾年的開發及用途

第16章 SWOT分析

第17章 結論

第18章 採訪記錄

  • 本章概要
  • Kirti Maheshwari, Chief Technical Officer, Intas Pharmaceuticals
  • Kevin Cancelliere and Tibor Hlobik, Marketing Directors, West Pharmaceutical Services
  • Rondald Wheet, Chief Executive Officer, Revolutions Medical
  • Matthew Young, Founder and Chief Technology Officer, Oval Medical Technologies

第19章 附錄1:表格形式資料

第20章 附錄2:企業清單

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: 10073

Injectable drug delivery systems have traversed a long way from conventional syringes with vials to prefilled syringes, autoinjectors, pen injectors and needle free systems. These modern devices have become preferred devices for parenteral administration of drugs. Specifically, the demand for prefilled syringes has been rising strongly over the past several years. A growing number of healthcare facilities are now adopting this format for delivering drugs. The popularity of prefilled syringes is not limited to healthcare settings; self-injecting patients looking for easier and safer methods also prefer using prefilled syringes for drug administration in home settings. The rise in parenteral drugs, especially biologics for the treatment of diseases and chronic conditions, such as multiple sclerosis and rheumatoid arthritis, has forced drug and packaging manufacturers to seek more sophisticated container closure and drug delivery systems. Responding to this increasing preference, pharmaceutical companies are now packaging a number of their injectable drugs and vaccines in prefilled syringe format. Over 100 injectable drug products are available in prefilled syringes and a rising number of pipeline drugs are targeted to be delivered by this method.

The origins of prefilled syringes can be traced back to the early 1980s when Sanofi and Rhone Poulenc-Rorer (Sanofi-Aventis) introduced them as drug delivery devices for heparins in Europe. They have been around for more than three decades now and are used for administration of all major classes of therapeutics, including vaccines, anticoagulants, anti-arthritic drugs and anti-anemic drugs. Prefilled syringes have improved significantly over the years. Manufacturers have recently developed multi-chamber syringes for use with lyophilized drugs. Such syringes are also being integrated with advanced injection devices, such as autoinjectors and pen injectors. In addition, prefilled diluent syringes and flush syringes are already quite popular. With more than 60% of candidate drugs / therapies in the clinical pipeline being biologics that usually require parenteral administration, the adoption of prefilled syringes is anticipated to further increase in the mid-long term.

Synopsis

The 'Prefilled Syringes Market (4th edition), 2017-2026 ' report provides a comprehensive analysis of the current state of prefilled syringes market and the likely future evolution of these devices over the next decade. Starting with an overview on prefilled syringes, the report elaborates on the development and manufacturing of prefilled syringes. It also includes information on needlestick injuries and provides an overview of the safety laws and legislations related to prefilled syringes across the major markets in the world.

Some of the key objectives of the report were to enumerate the various prefilled syringe systems that are available in the market, identify the drugs that are available in such dosage forms and estimate their corresponding market potential across different geographical regions. Specifically, the report includes insights on:

  • The current state of the market with respect to key players, targeted disease indications and the therapeutic classes of drugs that are available in the form of prefilled syringes, including a brief overview of biologics and biosimilars that are considered to be one of the primary growth drivers of this market.
  • The key drugs that are available in prefilled syringes; this has been presented in the form of detailed case studies.
  • The regulatory landscape in different countries, including the guidelines related to the grant of a marketing authorization for drugs in prefilled syringes.
  • The candidates that are likely to be tried for delivery via prefilled syringes in the future. It is worth highlighting that the candidates were chosen based on various parameters, such as their current route of administration, targeted indication and dosage frequency.
  • The key prefilled syringe and component manufacturers based in different geographies.
  • Product competitiveness and supplier power (in the form of 2 X 2 matrices) across the growing landscape of glass and plastic prefilled syringes.
  • Specialty syringes, which include prefilled flush syringes, prefilled diluent systems and contrast agents in prefilled syringes.
  • The contract manufacturing organizations providing fill / finish services related to prefilled syringes.
  • Future growth opportunities that are likely to drive the market in the short and long terms.

The study also features a detailed analysis of the existing market size and the potential future growth opportunities of these drug delivery devices across different classes of therapeutics. The analysis includes volumetric (number of units of prefilled syringes) and financial (future market size) projections of the market's evolution over the next ten years (2017-2026). We have provided insights on the regional evolution of the prefilled syringes market covering North America, Europe (UK, France, Italy, Spain, Germany and the rest of Europe), Latin America (Brazil, Mexico, Argentina and the rest of Latin America), Asia Pacific (Japan, China, India, South Korea and the rest of Asia Pacific), and the Middle East and Africa (Saudi Arabia, UAE, Africa and the rest of the Middle East). In addition, we have provided the likely evolution distributed by the type of material (glass and plastic), and nature of molecules (vaccines, biosynthetic insulins, synthetic pentasaccharides, monoclonal antibodies, small molecules). The forecast takes into account the impending price variations that are likely to emerge in the mid-long term as a result of growing adoption and increased competition. In order to account for the uncertainties associated with drug development and production, we have forecasted three different market scenarios, depicting conservative, base and optimistic tracks of the industry's evolution.

The opinions and insights presented in this study were influenced by discussions conducted with experts in this field. These included contributions from Kevin Cancelliere and Tibor Hlobik (Marketing Directors, West Pharmaceutical Services), Kirti Maheshwari (Chief Technical Officer, Intas Pharmaceuticals), Matthew Young (Founder and Chief Technology Officer, Oval Medical Technologies), and Rondald Wheet (Chief Executive Officer, Revolutions Medical). All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this report are in USD, unless otherwise specified.

Example Highlights

  • 1.Currently, more than 100 drugs and vaccines are available in prefilled syringes across different therapeutic classes. Humira®, Enbrel®, Copaxone®, Lovenox®, Rebif® and Pegasys® are examples of blockbuster drugs that are being extensively administered via prefilled syringes. In addition, over 65 drugs in prefilled syringe format are in clinical development for the treatment of number of indications such as rheumatoid arthritis and multiple sclerosis.
  • 2.The rise of biologics has emerged as a major growth driver. Additionally, a number of biologics are getting off patent in the coming few years. Biosimilar developers will be competing for the same drug and, in such situations, use of prefilled syringes as a mode of administration can act as a key differentiator. The market's evolution in the long-term will be fueled by pipeline drugs, technological advances and the rising adoption in developing markets. Moreover, integration of prefilled syringes with advanced delivery systems such as pen and autoinjectors will aid in gaining wider adoption.
  • 3.The development and launch of dual / multi-chambered syringes and prefilled diluent syringes has enabled easier and faster delivery of lyophilized drugs. Novel lubrication technologies such as TriboFilm Research's TriboGlide® and Becton Dickinson's XSi™ coating technologies have been introduced to overcome the problems associated with the use of silicone oil. Additionally, the design and availability of silicone-free and tungsten-free syringes is making them more suitable for use with sensitive drugs such as biologics.
  • 4.The current market is highly consolidated and is dominated by a handful of key manufacturers such as Becton Dickinson, Gerresheimer, SCHOTT, and Nuova Ompi. Other key players include West Pharmaceutical Services and Vetter Pharma; these players have already driven some novel devices and technologies in the market and are likely to foster more innovation.
  • 5.Many regional players have recently surfaced. Specifically in China, which has a large home consumer market, domestic players have an installed annual production capacity of as high as 150 million units; Shandong Weigao Group Medical Polymer Company, Shandong Zibo Minkang Pharmaceutical Packing, and Shandong Pharmaceutical Glass are well-known players. In Japan, Arte Corporation, Nipro Corporation, Taisei Kako and Terumo Corporation are known manufacturers of prefilled syringes; similarly, Roselabs Group, an India based manufacturer has invested heavily in this area.
  • 6.Aseptic filling of sterile drugs into prefilled syringes is one of the most crucial steps in pharmaceutical production. During the course of our study, we identified more than 45 contract manufacturing organizations, which provide fill and finish services for prefilled syringes. Majority (~70%) of the fill and finish service providers are based in North America and Europe. Prominent players in these regions include Biopharma Solutions, Catalent, Pfizer CentreOne, Rovi CM and Boehringer Ingelheim BioXcellence. Some well-known fill and finish service providers based in emerging markets include Cipla BioTec, DM Bio, Genovior Biotech and The Birgi Mefar Group.
  • 7.We anticipate the global prefilled syringe market to grow at an annualized rate of 3.9% between 2016 and 2026. The majority share of the prefilled syringes market is currently divided between North America (35%) and the EU (45%). We believe that the prefilled syringes markets in Asia, Latin America, the Middle East and Africa are likely to grow at faster rate than those of the more developed regions.

Research Methodology

Most of the data presented in this report has been gathered via secondary and primary research. For all our projects, we conduct interviews with experts in the area (academia, industry, medical practice and other associations) to solicit their opinions on emerging trends in the market. This is primarily useful for us to draw out our own opinion on how the market will evolve across different regions and technology segments. Where possible, the available data has been checked for accuracy from multiple sources of information.

The secondary sources of information include

  • Annual reports
  • Investor presentations
  • SEC filings
  • Industry databases
  • News releases from company websites
  • Government policy documents
  • Industry analysts' views

While the focus has been on forecasting the market over the coming ten years, the report also provides our view on various technological and non-commercial trends emerging in the industry. This opinion is solely based on our knowledge, research and understanding of the relevant market gathered from various secondary and primary sources of information.

Chapter Outlines

Chapter 2 provides an executive summary of the insights captured in our research and offers a high level view on where the market for prefilled syringes is headed in the mid-long term.

Chapter 3 provides a general overview of prefilled syringes, including details on their origin, required components (barrel, lock adapter, lubricant, needle, needle shield, plunger rod / piston, plunger stopper and tip cap) and manufacturing material (glass and plastic) . The chapter outlines the various types of prefilled syringe systems that are available in the market and provides details on the companies that manufacture such products. It also includes a discussion on the technological advances that have taken place in the recent past.

Chapter 4 highlights the growing concerns associated with needlestick injuries and the various legislative steps that have been taken to prevent them. These include installing various safety features in modern versions of prefilled syringes. In addition, the chapter provides information on some of the safety systems, including both add-on devices and device integrated features, and the companies involved in developing and manufacturing such solutions.

Chapter 5 presents information on the regulatory environment related to the grant of marketing authorizations for combination products across different countries. It highlights the role of regulatory bodies in the approval of prefilled syringes in North America, Europe, Latin America, Asia Pacific and the Middle East.

Chapter 6 features a detailed discussion on the key growth drivers of the prefilled syringes market. It also describes the rise in the number of chronic diseases, the growing trend of self-injection, changing patient demographics, and the emergence of biologics / biosimilars.

Chapter 7 provides details of the various products available in the form of prefilled syringes, primarily focusing on injectable drugs and vaccines. The chapter includes case studies of some of the marketed drugs available as prefilled syringes, such as Humira®, Enbrel®, Copaxone®, Lovenox® and Abilify Maintena®. We have also captured details on the molecules that are under clinical development as prefilled syringes. The chapter features a grid analysis, representing the distribution of pipeline drugs across different therapeutic areas and different stages of clinical development. Additionally, the chapter outlines major therapeutic drug classes that are available as prefilled syringes. For each therapeutic class, we have identified the drugs that are already available in prefilled syringes, their estimated patent expiry dates and corresponding generics / biosimilars that are under development.

Chapter 8 presents a list of drug candidates (marketed / pipeline) that are likely to be tried for delivery via prefilled syringes in the future. This list is based on insights gathered on the respective routes of administration of these candidates, the nature of the indication they are prescribed for, dosage frequency and annual sales (in case of marketed drugs).

Chapter 9 provides detailed profiles of some of the key manufacturers of prefilled syringes based in different geographies. Each profile includes a brief overview of the company, its financial information, product portfolio, technology platforms, recent facility expansions and / or acquisitions, and a comprehensive future outlook. The companies that have been included in this section include Aguettant, Becton Dickinson, Gerresheimer, Nipro Corporation, Nuova Ompi, SCHOTT, Terumo Corporation, Unilife, Vetter Pharma, Weigao Group Pharmaceutical Packaging Products Company and West Pharmaceutical Services. In addition, we have included brief profiles of some of the key prefilled syringe manufacturers that are based in emerging markets. The chapter also presents 2 X 2 matrix representations, comparing product competitiveness and supplier power of both glass and plastic prefilled syringes.

Chapter 10 provides insights on the various prefilled syringe component manufacturers along with details of their respective product portfolios. The key players covered in this section include Aptar Stelmi, Datwyler and West Pharmaceutical Services.

Chapter 11 provides information on fill and finish activities and the processes and technologies associated with them. The chapter highlights the importance of aseptic fill and finish operations, and features a discussion on future trends in this segment. It also includes detailed profiles of the global players that are engaged in this segment of the industry.

Chapter 12 features information on specialty syringes, namely prefilled flush syringes, prefilled diluent systems and contrast agents that are supplied in prefilled syringes. For each type of specialty syringe, we have provided a brief overview and presented details such as the different products that are available in the market and their advantages.

Chapter 13 offers a comprehensive perspective on how the prefilled syringe market is likely to evolve over the next ten years. Based on data collected through secondary research and insights from primary research, we adopted a top-down approach in order to estimate the future size of the market, both in terms of volume (number of units) and value (in USD billion). We have projected the market's evolution North America, Europe (UK, France, Italy, Spain, Germany and the rest of Europe), Latin America (Brazil, Mexico, Argentina and the rest of Latin America), Asia Pacific (Japan, China, India, South Korea and the rest of Asia Pacific), and the Middle East and Africa (Saudi Arabia, UAE, Africa and the rest of the Middle East). In addition, we have looked at the market's evolution by the type of material (glass and plastic) used and the nature of the product contained within the syringe (vaccines, biosynthetic insulins, synthetic pentasaccharides, monoclonal antibodies, small molecules and others). The analysis presents insightful 2 X 2 matrices based on Market Share and Market Attractiveness derived from the current and likely future state of the market.

Chapter 14 presents a list of autoinjectors that utilize prefilled syringes as their primary containers. In this chapter, we have included profiles of manufacturers of such autoinjectors, featuring an overview of the company and respective product portfolios. The key players that have been covered in this section include Bespak, DALI Medical Devices, Elcam Medical, Nuance Owen Mumford, SHL Group, Union Medico and Ypsomed Delivery Systems.

Chapter 15 discusses the recent technological developments in this domain and their applications. The chapter provides details on the advances in design technology and manufacturing of prefilled syringes that have enabled pharmaceutical companies to market lyophilized drugs in dual / multi chambered systems. The chapter highlights the advances related to novel lubrication and sterilization technologies as well.

Chapter 16 provides a comprehensive SWOT analysis of the prefilled syringes market. The chapter presents strategic insights on major factors that have contributed to the growth of the market, while highlighting the weaknesses and threats that are likely to have an impact on its future.

Chapter 17 summarizes the overall report. In this chapter, we have provided a recap of the key takeaways and expressed our independent opinion, based on the research and analysis described in previous chapters, on how the market is likely to fare in the shot and long terms.

Chapter 18 is a collection of interview transcripts of our discussions with some of the key players in this industry. In this chapter, we have presented the details of our conversations with Kevin Cancelliere and Tibor Hlobik (Marketing Directors, West Pharmaceutical Services), Kirti Maheshwari (Chief Technical Officer, Intas Pharmaceuticals), Matthew Young (Founder and Chief Technology Officer, Oval Medical Technologies), and Rondald Wheet (Chief Executive Officer, Revolutions Medical).

Chapters 19 and 20 are appendices, which provide tabulated data of all the charts and the list of companies that are mentioned in the report.

Table of Contents

1. Preface

  • 1.1. Scope of the Report
  • 1.2. Research Methodology
  • 1.3. Chapter Outlines

2. Executive Summary

3. Introduction to Prefilled Syringes

  • 3.1. Chapter Overview
  • 3.2. History of Prefilled Syringes
  • 3.3. Benefits of Prefilled Syringes over Traditional Injectable Devices
    • 3.3.1. Benefits for Healthcare Professionals and End Users
    • 3.3.2. Benefits for Manufacturers
    • 3.3.3. Shift of Existing Formulations to Prefilled Syringes
  • 3.4. Prefilled Syringes Components
  • 3.5. Classification of Prefilled Syringes
    • 3.5.1. Classification by Manufacturing Material of the Barrel
      • 3.5.1.1. Glass: Historical Material of Choice
      • 3.5.1.2. Limitations of Glass Prefilled Syringes
      • 3.5.1.3. Addressing the Limitations of Glass Prefilled Syringes
      • 3.5.1.4. Advantages of Plastic Prefilled Syringes
      • 3.5.1.5. Slow Adoption of Plastic Prefilled Syringes
      • 3.5.1.6. Factors Likely to Drive the Use of Plastic Prefilled Syringes
    • 3.5.2. Classification by Number of Chambers in the Barrel
    • 3.5.3. Classification by Type of Needle
    • 3.5.4. Classification by Type of Processing
  • 3.6. Critical Attributes of a Prefilled Syringe Design
  • 3.7. Prefilled Syringe Systems Available in the Market
    • 3.7.1. Glass Prefilled Syringes
    • 3.7.2. Plastic Prefilled Syringes
  • 3.8. Technological Developments in Prefilled Syringes

4. Needlestick Injuries

  • 4.1. Chapter Overview
  • 4.2. Incidence and Cost Burden
  • 4.3. Government Legislations for Needlestick Injury Prevention
  • 4.4. Safety Mechanisms used by Prefilled Syringe Manufacturers
    • 4.4.1. Safety Systems: Add-On Devices
      • 4.4.1.1. Becton Dickinson
      • 4.4.1.2. Gerresheimer
      • 4.4.1.3. West Pharmaceutical Services
      • 4.4.1.4. Vetter Pharma
      • 4.4.1.5. Tip-Top
      • 4.4.1.6. Credence MedSystems
      • 4.4.1.7. Schreiner MediPharm
    • 4.4.2. Safety Systems: Integrated Devices
      • 4.4.2.1. Unilife Corporation: Unifill Safety Syringes
      • 4.4.2.2. MedPro Safety Products: Prefilled Safety Syringes
      • 4.4.2.3. Taisei Kako: Fulject™ Safety Syringes
      • 4.4.2.4. Globe Medical Tech: Vacuum Retract Safety Syringes
      • 4.4.2.5. US Medical Instruments: SafeSnap®
      • 4.4.2.6. Revolutions Medical: RevVac™ Safety Syringes
      • 4.4.2.7. MedicalChain International: MySafill® iPPFSS
      • 4.4.2.8. Owen Mumford: Unisafe™

5. Regulatory Landscape for Prefilled Syringes

  • 5.1. Chapter Overview
  • 5.2. Regulatory Approval of Combination Products in the US
    • 5.2.1. Overview
    • 5.2.2. Historical Background
    • 5.2.3. Regulatory Bodies and their Role in Product Approval
    • 5.2.4. Regulatory Approval Pathway for Prefilled Syringes
  • 5.3. Regulatory Approval of Combination Products in Europe
    • 5.3.1. Overview
    • 5.3.2. Regulatory Bodies and their Role in Product Approval
    • 5.3.3. Regulatory Approval for Prefilled Syringes
  • 5.4. Regulatory Approval of Combination Products in Canada
    • 5.4.1. Overview
    • 5.4.2. Regulatory Bodies and their Role in Product Approval
    • 5.4.3. Regulatory Approval of Prefilled Syringes
  • 5.5. Regulatory Approval of Combination Products in Brazil
    • 5.5.1. Overview
    • 5.5.2. Regulatory Bodies and their Role in Product Approval
    • 5.5.3. Regulatory Approval of Prefilled Syringes
  • 5.6. Regulatory Approval of Combination Products in Mexico
    • 5.6.1. Overview
    • 5.6.2. Regulatory Bodies and their Role in Product Approval
    • 5.6.3. Regulatory Approval of Prefilled Syringes
  • 5.7. Regulatory Approval of Combination Products in Argentina
    • 5.7.1. Overview
    • 5.7.2. Regulatory Bodies and their Role in Product Approval
    • 5.7.3. Regulatory Approval of Prefilled Syringes
  • 5.8. Regulatory Approval of Combination Products in Australia
    • 5.8.1. Overview
    • 5.8.2. Regulatory Bodies and their Role in Product Approval
    • 5.8.3. Regulatory Approval of Prefilled Syringes
  • 5.9. Regulatory Approval of Combination Products in Japan
    • 5.9.1. Overview
    • 5.9.2. Regulatory Bodies and their Role in Product Approval
    • 5.9.3. Regulatory Approval of Prefilled syringes
  • 5.10. Regulatory Approval of Combination Products in China
    • 5.10.1. Overview
    • 5.10.2. Regulatory Bodies and their Role in Product Approval
    • 5.10.3. Regulatory Approval of Prefilled syringes
  • 5.11. Regulatory Approval of Combination Products in India
    • 5.11.1. Overview
    • 5.11.2. Regulatory Bodies and their Role in Product Approval
    • 5.11.3. Regulatory Approval of Prefilled Syringes
  • 5.12. Regulatory Approval of Combination Products in South Korea
    • 5.12.1. Overview
    • 5.12.2. Regulatory Bodies and their Role in Product Approval
    • 5.12.3. Regulatory Approval of Prefilled Syringes
  • 5.13. Regulatory Approval of Combination Products in Saudi Arabia
    • 5.13.1. Overview
    • 5.13.2. Regulatory Bodies and their Role in Product Approval
  • 5.14. Regulatory Approval of Prefilled Syringes
  • 5.15. Regulatory Approval of Combination Products in United Arab Emirates
    • 5.15.1. Overview
    • 5.15.2. Regulatory Bodies and their Role in Product Approval
    • 5.15.3. Regulatory Approval of Prefilled Syringes

6. Growth Drivers

  • 6.1. Chapter Overview
  • 6.2. Increase in the Number of Self-Injecting Patients
  • 6.3. Increase in Incidences of Chronic Diseases
  • 6.4. Changing Patient Demographics
  • 6.5. Growth of Biologics and Biosimilars
  • 6.6. Changing Pharmaceutical Strategies
  • 6.7. Increasing Focus on the Prevention of Needlestick Injuries
  • 6.8. Convergence of Prefilled Syringes with Autoinjectors/Pen-Injectors

7. Products Available in Prefilled Syringes

  • 7.1. Chapter Overview
  • 7.2. Drugs Approved in Prefilled Syringes, 2013-2016
  • 7.3. Drugs Approved in Prefilled Syringes: Therapeutic Area Analysis
  • 7.4. Leading Drugs in Prefilled Syringes, 2016
  • 7.5. Other Drugs Available in Prefilled Syringes, 2016
  • 7.6. Case Studies
    • 7.6.1. HUMIRA® (Adalimumab), AbbVie / Eisai
      • 7.6.1.1. Indications and Dosage Forms
      • 7.6.1.2. Shift from Vials to Syringes
    • 7.6.2. Enbrel® (Etanercept), Amgen / Pfizer / Takeda
      • 7.6.2.1. Indications and Dosage Forms
      • 7.6.2.2. Shift from Vials to Syringes
    • 7.6.3. Copaxone® (Glatiramer Acetate), Teva Pharmaceuticals
      • 7.6.3.1. Indications and Dosage Forms
      • 7.6.3.2. Shift from Vials to Syringes
    • 7.6.4. Lovenox® / Clexane® (Enoxaparin sodium), Sanofi / GL Pharma / Italfarmaco
      • 7.6.4.1. Indications and Dosage Forms
      • 7.6.4.2. Shift from Vials to Prefilled Syringes
    • 7.6.5. Abilify Maintena® (Aripiprazole Controlled Release), Otsuka Pharmaceutical / Lundbeck
      • 7.6.5.1. Indications and Dosage Forms
      • 7.6.5.2. Shift from Vials to Syringes
  • 7.7. Pipeline Drugs in Prefilled Syringes
  • 7.8. Pipeline Drugs: Therapeutic Area Analysis
  • 7.9. Drugs Available by Therapeutic Classes
    • 7.9.1. Anti-Rheumatics
      • 7.9.1.1. Approved Injectables
      • 7.9.1.2. Biosimilars
    • 7.9.2. Multiple Sclerosis Drugs
      • 7.9.2.1. Approved Injectables
      • 7.9.2.2. Biosimilars
    • 7.9.3. Antivirals
      • 7.9.3.1. Approved Injectables
      • 7.9.3.2. Biosimilars
    • 7.9.4. Anticoagulants
      • 7.9.4.1. Approved Injectables
      • 7.9.4.2. Biosimilars / Generics
    • 7.9.5. Vaccines
    • 7.9.6. Diabetes Drugs
      • 7.9.6.1. Insulin Market
      • 7.9.6.2. Approved Injectables
      • 7.9.6.3. Biosimilars

8. Likely Candidates for Prefilled Syringes

  • 8.1. Chapter Overview
  • 8.2. Marketed Molecules
    • 8.2.1. Marketed Molecules: Likely Candidates for Prefilled Syringes
  • 8.3. Pipeline Molecules
    • 8.3.1. Pipeline Molecules: Most Likely Candidates for Prefilled Syringes
    • 8.3.2. Pipeline Molecules: Likely Candidates for Prefilled Syringes
    • 8.3.3. Pipeline Molecules: Less Likely Candidates for Prefilled Syringes
  • 8.4. Vaccines: Likely Candidates for Prefilled Syringes

9. Manufacturers of Prefilled Syringes

  • 9.1. Chapter Overview
  • 9.2. Key Prefilled Syringe Manufacturers Based in North America
    • 9.2.1. Becton Dickinson
      • 9.2.1.1. Company Overview
      • 9.2.1.2. Financial Performance
      • 9.2.1.3. Glass Prefilled Systems
        • 9.2.1.3.1. BD Hypak™ Prefilled Syringe
        • 9.2.1.3.2. Luer Products
        • 9.2.1.3.3. Staked Needle Products
        • 9.2.1.3.4. BD Neopak™ Prefilled Syringe
      • 9.2.1.4. Plastic Prefilled Systems
        • 9.2.1.4.1. BD Sterifill™ Syringe Systems
      • 9.2.1.5. Other Prefilled Delivery Systems
        • 9.2.1.5.1. BD Uniject™
        • 9.2.1.5.2. BD Soluvia™
      • 9.2.1.6. BD Prefilled Technology Solutions
      • 9.2.1.7. Recent Developments
        • 9.2.1.7.1. Deals and Agreements
        • 9.2.1.7.2. Expansions
      • 9.2.1.8. Future Outlook
    • 9.2.2. Unilife Corporation
      • 9.2.2.1. Company Overview
      • 9.2.2.2. Financial Performance
      • 9.2.2.3. Glass Prefilled Syringe
        • 9.2.2.3.1. Unifill® Syringes
        • 9.2.2.3.2. EZMix™ Syringes
      • 9.2.2.4. Wearable Injector Platform
      • 9.2.2.5. Ocular Delivery Systems
      • 9.2.2.6. Novel Delivery Systems
      • 9.2.2.7. Recent Developments
        • 9.2.2.7.1. Deals and Agreements
          • 9.2.2.7.1.1. Partnership with Amgen
          • 9.2.2.7.1.2. Partnership with MedImmune
          • 9.2.2.7.1.3. Partnership with AbbVie
          • 9.2.2.7.1.4. Partnership with Global Pharma Company
          • 9.2.2.7.1.5. Partnership with Novartis
          • 9.2.2.7.1.6. Partnership with Hikma
          • 9.2.2.7.1.7. Partnership with Sanofi
          • 9.2.2.7.1.8. Partnership with Biodel
        • 9.2.2.7.2. Expansion
        • 9.2.2.7.3. Fundings
      • 9.2.2.8. Future Outlook
    • 9.2.3. West Pharmaceutical Services
      • 9.2.3.1. Company Overview
      • 9.2.3.2. Financial Performance
      • 9.2.3.3. Plastic Prefilled Systems
        • 9.2.3.3.1. Daikyo Crystal Zenith® RU Prefilled Syringe
      • 9.2.3.4. Drug Reconstitution Systems
      • 9.2.3.5. Prefilled Technology Solutions
      • 9.2.3.6. Recent Developments
        • 9.2.3.6.1. Growth of CZ Syringes
        • 9.2.3.6.2. Launch of NovaPure Plunger for Higher Volume Injections
        • 9.2.3.6.3. Growth in Pharma Emerging Markets (Brazil, China and India)
        • 9.2.3.6.4. Manufacturing Expansion
        • 9.2.3.6.5. Development Pipeline
      • 9.2.3.7. Future Outlook
  • 9.3. Key Prefilled Syringe Manufacturers Based in Europe
    • 9.3.1. Aguettant
      • 9.3.1.1. Company Overview
      • 9.3.1.2. Aguettant Prefilled Syringes
      • 9.3.1.3. Aguettant Self-Injector Pen
      • 9.3.1.4. Recent Developments
      • 9.3.1.5. Future Outlook
    • 9.3.2. Gerresheimer
      • 9.3.2.1. Company Overview
      • 9.3.2.2. Financial Performance
      • 9.3.2.3. Glass Prefilled Systems
        • 9.3.2.3.1. Gx® Glass Syringes
      • 9.3.2.4. Plastic Prefilled Systems
        • 9.3.2.4.1. ClearJect® Prefilled Syringes
        • 9.3.2.4.2. Gx RTF® Clearject® Needle Syringe
      • 9.3.2.5. Self-Injection Devices
      • 9.3.2.6. Prefilled Technology Solutions
      • 9.3.2.7. Recent Developments
        • 9.3.2.7.1. Expansion of Product Portfolio
        • 9.3.2.7.2. Expansion of Manufacturing Capacity for RTF syringes
        • 9.3.2.7.3. Expansion of Capacity of Medical Plastic Systems
        • 9.3.2.7.4. Growth in Emerging Economies
      • 9.3.2.8. Future Outlook
    • 9.3.3. Nuova Ompi
      • 9.3.3.1. Company Overview
      • 9.3.3.2. Financial Performance
      • 9.3.3.3. Glass Prefilled Systems
        • 9.3.3.3.1. EZ-Fill® Syringes
      • 9.3.3.4. Recent Developments
        • 9.3.3.4.1. New Corporate Branding
        • 9.3.3.4.2. Capacity Expansion across the Glass Divisions
        • 9.3.3.4.3. Twist-Off Closure System for Prefilled Syringes
    • 9.3.4. SCHOTT
      • 9.3.4.1. Company Overview
      • 9.3.4.2. Financial Performance
      • 9.3.4.3. Glass Prefilled Syringes
        • 9.3.4.3.1. syriQ® (Previously Forma 3s) Glass Syringes
        • 9.3.4.3.2. syriQ™ InJentle Syringes
      • 9.3.4.4. Plastic Prefilled Syringes
        • 9.3.4.4.1. TopPac® Polymer Syringes
      • 9.3.4.5. Recent Developments
        • 9.3.4.5.1. TopPac® Syringe System for Sensitive Drugs
        • 9.3.4.5.2. TopPac® Syringe System for Highly Viscous Drugs
        • 9.3.4.5.3. TopPac® 20 ml Syringe System for Infusion Therapy
        • 9.3.4.5.4. Rebranding the Glass Prefilled Syringes
        • 9.3.4.5.5. New Closure Systems for Plastic / Glass Prefilled System
        • 9.3.4.5.6. Growth in the Pharma Emerging Markets (Brazil, China, India, Indonesia and Russia)
        • 9.3.4.5.7. Expansion of Production Facilities in the US and EU
      • 9.3.4.6. Future Outlook
    • 9.3.5. Vetter Pharma
      • 9.3.5.1. Company Overview
      • 9.3.5.2. Lyo-Ject® Glass Prefilled Syringe
      • 9.3.5.3. Vetter-Ject®
      • 9.3.5.4. Recent Developments
        • 9.3.5.4.1. Capacity Expansion
        • 9.3.5.4.2. Collaboration with West Pharmaceutical Services
      • 9.3.5.5. Future Outlook
  • 9.4. Key Prefilled Syringes Manufacturers Based in Asia Pacific
    • 9.4.1. Nipro Corporation (Acquired MGlas)
      • 9.4.1.1. Company Overview
      • 9.4.1.2. Financial Performance
      • 9.4.1.3. Glass Prefilled Systems
      • 9.4.1.4. Plastic Prefilled Systems
      • 9.4.1.5. Recent Developments
      • 9.4.1.6. Future Outlook
    • 9.4.2. Weigao Group Pharmaceutical Packaging Products Company
      • 9.4.2.1. Company Overview
      • 9.4.2.2. Financial Performance
      • 9.4.2.3. WeGo Glass Prefilled Syringe
      • 9.4.2.4. Future Outlook
    • 9.4.3. Terumo Corporation
      • 9.4.3.1. Company Overview
      • 9.4.3.2. Financial Performance
      • 9.4.3.3. PLAJEX™: Plastic Prefilled Syringe
      • 9.4.3.4. Safety Devices: Add-On Devices
      • 9.4.3.5. Future Outlook
  • 9.5. Other Manufacturers
    • 9.5.1. Arte Corporation
    • 9.5.2. J.O. Pharma (Subsidiary of Otsuka Holdings)
    • 9.5.3. Roselabs Group
    • 9.5.4. Shandong Zibo Minkang Pharmaceutical packing
    • 9.5.5. Shandong Pharmaceutical Glass
    • 9.5.6. Taisei Kako
    • 9.5.7. Yangzhong Wealth Metal
    • 9.5.8. Youlyy Industrial
  • 9.6. Mapping the Competitive Landscape

10. Prefilled Syringe Component Manufacturers

  • 10.1. Chapter Overview
  • 10.2. West Pharmaceutical Services
    • 10.2.1. Overview
    • 10.2.2. Financial Performance
    • 10.2.3. Prefilled Syringe Components
      • 10.2.3.1. Plungers
      • 10.2.3.2. Needle Shields and Tip Caps
      • 10.2.3.3. Backstops
    • 10.2.4. Manufacturing Facilities
  • 10.3. Datwyler
    • 10.3.1. Overview
    • 10.3.2. Financial Performance
    • 10.3.3. Prefilled Syringe Components
      • 10.3.3.1. Plungers
      • 10.3.3.2. Needle Shields and Tip Caps
    • 10.3.4. Manufacturing of Prefilled Syringe Components
  • 10.4. Aptar Stelmi
    • 10.4.1. Overview
    • 10.4.2. Financial Performance
    • 10.4.3. Prefilled Syringe Components
      • 10.4.3.1. Plungers
      • 10.4.3.2. Needle Shields
      • 10.4.3.3. Tip Caps
      • 10.4.3.4. Stoppers

11. Fill-Finish Service Providers for Prefilled Syringes

  • 11.1. Chapter Overview
  • 11.2. Fill-Finish Processing of Prefilled Syringes
    • 11.2.1. Steps Involved in Fill-Finish Process
    • 11.2.2. Methods of Filling and Stoppering of Prefilled Syringes
    • 11.2.3. Prefilled Syringe Filling Technologies
  • 11.3. Outsourcing of Fill-Finish Operations
  • 11.4. Growth Considerations
  • 11.5. Fill-Finish Service Providers
    • 11.5.1. Key Fill-Finish Service Provider(s): North America
      • 11.5.1.1. BioPharma Solutions
      • 11.5.1.2. Catalent
      • 11.5.1.3. Pfizer CentreOne
    • 11.5.2. Key Fill-Finish Service Provider(s): Latin America
      • 11.5.2.1. PiSA Farmaceutica
    • 11.5.3. Key Fill-Finish Service Provider(s): Europe
      • 11.5.3.1. Boehringer Ingelheim BioXcellence
      • 11.5.3.2. ROVI CM
    • 11.5.4. Key Fill-Finish Service Provider(s): Asia Pacific
      • 11.5.4.1. Cipla BioTec
      • 11.5.4.2. DM Bio
      • 11.5.4.3. Genovior Biotech
    • 11.5.5. Key Fill-Finish Service Provider(s): Middle East
      • 11.5.5.1. The Birgi Mefar Group

12. Specialty Prefilled Syringes

  • 12.1. Chapter Overview
  • 12.2. Prefilled Flush Syringes
    • 12.2.1. Overview
    • 12.2.2. Prefilled Flush Syringes Available in the Market
    • 12.2.3. Advantages of Prefilled Flush Syringes
  • 12.3. Prefilled Diluent Syringes
    • 12.3.1. Overview
    • 12.3.2. Lyophilized Drugs Available in Prefilled Diluent System
    • 12.3.3. Advantages of Prefilled Diluent Syringe Systems
  • 12.4. Contrast Agent Prefilled Syringes
    • 12.4.1. Overview
    • 12.4.2. Contrast Agents Available in Prefilled Syringes
    • 12.4.3. Advantages of Using Prefilled Syringe for Contrast Agents

13. Global Prefilled Syringes Market Forecast, 2016-2026

  • 13.1. Chapter Overview
  • 13.2. Scope and Methodology
  • 13.3. Global Market Size and Forecast
    • 13.3.1. Prefilled Syringes for Vaccines
    • 13.3.2. Prefilled Syringes for Drugs
      • 13.3.2.1. Prefilled Syringes for Anticoagulants
      • 13.3.2.2. Prefilled Syringes for Diabetes Drugs
      • 13.3.2.3. Prefilled Syringes for Multiple Sclerosis Drugs
      • 13.3.2.4. Prefilled Syringes for Anti-Arthritic Drugs
      • 13.3.2.5. Prefilled Syringes for Anti-Anemic Drugs
      • 13.3.2.6. Prefilled Syringes for Other Drug Classes
    • 13.3.3. Specialty Prefilled Syringes
    • 13.3.4. Overall Global Market Size
  • 13.4. Prefilled Syringe Market Forecast by Regions
    • 13.4.1. North America Prefilled Syringes Market
    • 13.4.2. EU Prefilled Syringes Market
    • 13.4.3. Asia Pacific Prefilled Syringes Market
    • 13.4.4. Latin America Prefilled Syringes Market
    • 13.4.5. Middle East and Africa Prefilled Syringes Market
    • 13.4.6. Prefilled Syringes Market Attractiveness Analysis by Region
  • 13.5. Prefilled Syringes Market Forecast by Type of Material
  • 13.6. Prefilled Syringes Market Forecast by Nature of Molecule
    • 13.6.1. Prefilled Syringes Market Attractiveness Analysis by Nature of Molecule

14. Case Study: Autoinjectors

  • 14.1. Chapter Overview
  • 14.2. Autoinjectors: Market Overview
  • 14.3. Key Players
    • 14.3.1. Bespak
      • 14.3.1.1. Company Overview
        • 14.3.1.2. Product Portfolio
          • 14.3.1.2.1. Autoinjectors
            • 14.3.1.2.1.1. Syrina™
            • 14.3.1.2.1.2. ASI Autoinjector™
            • 14.3.1.2.1.3. OTS Autoinjector™
    • 14.3.2. DALI Medical Devices
      • 14.3.2.1. Company Overview
      • 14.3.2.2. Product Portfolio
        • 14.3.2.2.1. Autoinjectors
          • 14.3.2.2.1.1. SAN-L
          • 14.3.2.2.1.2. SAN-P
          • 14.3.2.2.1.3. SAN-DV
          • 14.3.2.2.1.4. SAN-DV Pro
    • 14.3.3. Elcam Medical (E3D Elcam Drug Delivery Devices)
      • 14.3.3.1. Company Overview
      • 14.3.3.2. Product Portfolio
        • 14.3.3.2.1. Autoinjectors
        • 14.3.3.2.2. Flexi-Q Disposable Autoinjector
          • 14.3.3.2.2.1. Flexi-Q PFS
          • 14.3.3.2.2.2. Flexi-Q HV
          • 14.3.3.2.2.3. Flexi -Q DV
        • 14.3.3.2.3. Flexi-Q Reusable Autoinjectors
          • 14.3.3.2.3.1. Flexi-Q mMU
          • 14.3.3.2.3.2. Flexi-Q eMU
    • 14.3.4. Nuance Designs
      • 14.3.4.1. Company Overview
      • 14.3.4.2. Product Portfolio
        • 14.3.4.2.1. Fusion™ Autoinjector
        • 14.3.4.2.2. Quantum™ Autoinjector
    • 14.3.5. Owen Mumford
      • 14.3.5.1. Company Overview
      • 14.3.5.2. Product Portfolio
        • 14.3.5.2.1. Autoinjectors
          • 14.3.5.2.1.1. Autoject® Micro
          • 14.3.5.2.1.2. Autoject® 2
          • 14.3.5.2.1.3. Autoject® Mini
          • 14.3.5.2.1.4. Autoject® Uni
          • 14.3.5.2.1.5. Autoject® Multi
          • 14.3.5.2.1.6. Autoject® Flex
    • 14.3.6. Scandinavian Health Limited (SHL) Group
      • 14.3.6.1. Company Overview
      • 14.3.6.2. Product Portfolio
        • 14.3.6.2.1. Two-Step Disposable Autoinjectors
          • 14.3.6.2.1.1. Amber (Pushclick Technology)
          • 14.3.6.2.1.2. Molly®
          • 14.3.6.2.1.3. Molly® RNS
          • 14.3.6.2.1.4. Molly® 2.25
          • 14.3.6.2.1.5. Molly® C
          • 14.3.6.2.1.6. NAISA® (Negasai™ Spring Technology)
        • 14.3.6.2.2. Three-Step Disposable Autoinjectors
          • 14.3.6.2.2.1. DAI®
          • 14.3.6.2.2.2. DAI®-RNS
          • 14.3.6.2.2.3. DAI®-R
          • 14.3.6.2.2.4. SDI-MIX®+NIT™ (Needle Isolation Technology and Twist and Mix Mechanism)
          • 14.3.6.2.2.5. VSDI-MIX™
          • 14.3.6.2.2.6. PSDI®
        • 14.3.6.2.3. PPI® Injector (Rotaject Pressure Release Technology)
    • 14.3.7. Union Medico
      • 14.3.7.1. Company Overview
      • 14.3.7.2. Product Portfolio
        • 14.3.7.2.1. 45° Autoinjector
          • 14.3.7.2.1.1. 45°/S Autoinjector
          • 14.3.7.2.1.2. 45°/M Autoinjector
          • 14.3.7.2.1.3. 45°/R Autoinjector
        • 14.3.7.2.2. 90° Autoinjector
          • 14.3.7.2.2.1. 90°/S Autoinjector
          • 14.3.7.2.2.2. 90°/ M Autoinjector
          • 14.3.7.2.2.3. 90°/ XL Autoinjector
          • 14.3.7.2.2.4. SuperGrip™ Autoinjector
          • 14.3.7.2.2.5. Exclusive™ Autoinjector
    • 14.3.8. Ypsomed Delivery Systems
      • 14.3.8.1. Company Overview
      • 14.3.8.2. Product Portfolio
        • 14.3.8.2.1. Pen Injectors
        • 14.3.8.2.2. Autoinjectors
          • 14.3.8.2.2.1. YpsoMate® and YpsoMate® 2.25
          • 14.3.8.2.2.2. VarioJect™
          • 14.3.8.2.2.3. YpsoMate® Smart

15. Recent Developments and Applications of Prefilled Syringes

  • 15.1. Chapter Overview
  • 15.2. Prefilled Syringes for Lyophilized Drugs
    • 15.2.1. Prefilled Diluent Syringes
    • 15.2.2. Prefilled Dual / Multi-Chamber Syringes
    • 15.2.2.1. Lyophilized Drugs Available in Dual / Multi-Chamber Prefilled Syringe
    • 15.2.2.2. Prefilled Dual-Chambered Pen Injectors for Lyophilized Drugs
  • 15.3. Multilayer Plastic Prefilled Syringes with Oxygen Barrier
  • 15.4. Novel Lubrication Technology for Prefilled Syringes
  • 15.5. Advancement in Terminal Sterilization of Prefilled Syringes
    • 15.5.1. Noxilizer's Nitrogen Dioxide Sterilization Technology

16. SWOT Analysis

  • 16.1. Chapter Overview
  • 16.2. Strengths
  • 16.3. Weaknesses
  • 16.4. Opportunities
  • 16.5. Threats

17. Conclusion

  • 17.1. Prefilled Syringes have Emerged as the Preferred Administration Device for Parenteral Drugs
  • 17.2. Plastic Syringes are Anticipated to Grow at Faster Rate than Glass Syringes
  • 17.3. Emergence of Biologics, Technological Advances and Many Other Factors will Sustain the Growth
  • 17.4. Although the Market is Consolidated, New Entrants with Innovative Technologies are expected to Drive Future Evolution
  • 17.5. CMOs are an Integral Part of the Value Chain, Providing Aseptic Fill / Finish Services
  • 17.6. The Prefilled Syringes Market is Poised to Grow at a Moderate Pace over the Coming Decade
  • 17.7. Concluding Remarks

18. Interview Transcripts

  • 18.1. Chapter Overview
  • 18.2. Kirti Maheshwari, Chief Technical Officer, Intas Pharmaceuticals, Q3 2016
  • 18.3. Kevin Cancelliere and Tibor Hlobik, Marketing Directors, West Pharmaceutical Services, Q2 2015
  • 18.4. Rondald Wheet, Chief Executive Officer, Revolutions Medical, Q2 2015
  • 18.5. Matthew Young, Founder and Chief Technology Officer, Oval Medical Technologies, Q2 2014

19. Appendix 1: Tabulated Data

20. Appendix 2: List of Companies

List of Figures

  • Figure 2.1 Prefilled Syringes Market Evolution: 2016, 2021, and 2026 (Number of Units, Million)
  • Figure 2.2 Prefilled Syringes Market Landscape, 2016-2026: Geographic Trends
  • Figure 2.3 Prefilled Syringes Market Attractiveness Analysis by Region
  • Figure 2.4 Prefilled Syringes Market Attractiveness Analysis by Nature of Molecule
  • Figure 3.1 Glass Prefilled Syringes: Advantages and Disadvantages
  • Figure 3.2 Properties of Cyclic Olefin Copolymer and Cyclo Olefin Polymer
  • Figure 3.3 Plastic Prefilled Syringes: Advantages and Disadvantages
  • Figure 3.4 Critical Design Parameters of Prefilled Syringes
  • Figure 3.5 Prefilled Syringes: Market Landscape by Manufacturers
  • Figure 3.6 Technological Evolution of Prefilled Syringes
  • Figure 4.1 Worldwide Evolution in Healthcare Safety Legislation
  • Figure 5.1 Global Regulations Related to Prefilled Syringes
  • Figure 5.2 Approval Pathway for Combination Products in the US
  • Figure 5.3 Approval Pathway for Combination Products in Canada
  • Figure 5.4 Approval Pathway for Combination Products in China
  • Figure 6.1 Global Prevalence of Diabetes: Distribution by Countries, 2015 (Million, %)
  • Figure 6.2 Numbers of Biologics Approved by the USFDA, 2009-2016
  • Figure 6.3 Top Selling Biologics: Estimated Patent Expiry
  • Figure 7.1 Approved Drugs: Therapeutic Area Analysis (2013-2016)
  • Figure 7.2 Sales of Leading Drugs Available in Prefilled Syringes, 2016 (USD Million)
  • Figure 7.3 HUMIRA®: Approval Timeline (US, EU and Japan)
  • Figure 7.4 HUMIRA®: Approval Timeline for Various Dosage Forms (US and EU)
  • Figure 7.5 HUMIRA®: Annual Sales, 2003-Q3 2016 (USD Million)
  • Figure 7.6 Enbrel®: Approval Timeline (US and EU)
  • Figure 7.7 Enbrel®: Approval Timeline for Various Dosage Forms (US and EU)
  • Figure 7.8 Enbrel®: Annual Sales in the US and Canada, 2002-2015 (USD Million)
  • Figure 7.9 Enbrel®: Annual Sales outside US and Canada, 2010-2015 (USD Million)
  • Figure 7.10 Copaxone ®: Annual Sales, 2001-Q3 2016 (USD Million)
  • Figure 7.11 Copaxone ®: Distribution by Vials and Prefilled Syringes, 2000-2008 (Million Units)
  • Figure 7.12 Lovenox®: Approval Timeline (US)
  • Figure 7.13 Lovenox®: Global Annual Sales, 2009- Q3 2016 (EUR Million)
  • Figure 7.14 Abilify Maintena®: Approval Timeline (US, Canada, Europe, Japan)
  • Figure 7.15 Pipeline Drugs: Therapeutic Area Analysis
  • Figure 7.16 Number of Approved / Pipeline Biosimilars of Anti-Rheumatics
  • Figure 7.17 Number of Approved / Pipeline Biosimilars of Multiple Sclerosis Drugs
  • Figure 7.18 Number of Approved / Pipeline Biosimilars of Antivirals
  • Figure 7.19 Number of Approved / Pipeline Biosimilars and Generics of Anticoagulants
  • Figure 7.20 Number of Approved / Pipeline Biosimilars of Diabetes Drugs
  • Figure 8.1 Marketed Molecules: Parameters and Scoring Criteria
  • Figure 8.2 Pipeline Molecules: Parameters and Scoring Criteria
  • Figure 9.1 BD Medical: Annual Revenues, 2011-2016 (USD Billion)
  • Figure 9.2 BD Medical: Revenue Distribution by Sub-Segments, 2016 (USD Billion)
  • Figure 9.3 Unilife Corporation: Annual Revenues, FY 2011/12-2015/16 (USD Million)
  • Figure 9.4 West Pharmaceutical Services: Annual Revenues, 2011-Q3 2016 (USD Million)
  • Figure 9.5 West Pharmaceutical Services: Revenue Distribution by Business Segments, 2015 (USD Million)
  • Figure 9.6 West Pharmaceutical Services: Annual Revenues of Delivery Systems Segment, 2011-2015 (USD Million)
  • Figure 9.7 West Pharmaceutical Services: Annual Revenues in the US and Overseas, 2011-2015 (USD Million)
  • Figure 9.8 West Pharmaceutical Services: Revenue Distribution by Region, 2015 (USD Million)
  • Figure 9.9 Gerresheimer: Annual Revenues, 2011-Q3 2016 (EUR Million)
  • Figure 9.10 Gerresheimer: Revenue Distribution by Business Divisions, 2015 (EUR Million)
  • Figure 9.11 Gerresheimer: Revenue Distribution by Region, 2011- 2015 (EUR Million)
  • Figure 9.12 SCHOTT: Annual Revenues, FY 2012/13-FY 2014/15 (EUR Million)
  • Figure 9.13 SCHOTT: Revenue Distribution by Business Divisions, FY 2014/15 (EUR Million)
  • Figure 9.14 SCHOTT: Revenue Distribution by Region, FY 2014/15 (EUR Million)
  • Figure 9.15 Nipro Corporation: Annual Revenues, 2011/12-2015/16 (YEN Billion)
  • Figure 9.16 Nipro Corporation: Revenue Distribution by Business Divisions, 2015/16 (YEN Billion)
  • Figure 9.17 Nipro Corporation: Revenue Distribution by Region, 2015/16 (YEN Billion)
  • Figure 9.18 Nipro Corporation: Revenue Distribution by Region, 2011/12-2015/16 (YEN Billion)
  • Figure 9.19 Weigao: Annual Revenues of Prefilled Syringes, 2011-H1 2016 (RMB Million)
  • Figure 9.20 Weigao: Revenue Distribution by Product Category, 2015 (RMB Million)
  • Figure 9.21 Terumo Corporation: Annual Revenues, FY 2011-H1 2016 (YEN Billion)
  • Figure 9.22 Terumo Corporation: Revenue Distribution by Business Divisions, FY 2015/16 (YEN Billion)
  • Figure 9.23 Terumo Corporation: Revenue Distribution by Region, FY 2015/16 (YEN Billion)
  • Figure 9.24 Glass Prefilled Syringes: Product Landscape Analysis
  • Figure 9.25 Polymer Prefilled Syringes: Product Landscape Analysis
  • Figure 10.1 Datwyler Group: Annual Revenues, 2011-H1 2016 (CHF Million)
  • Figure 10.2 Datwyler Group: Revenue Distribution by Business Divisions, 2015 (CHF Million)
  • Figure 10.3 Aptar Stelmi: Annual Revenues, 2013-2015 (USD Million)
  • Figure 11.1 Prefilled Syringes: Fill-Finish Process
  • Figure 13.1 Prefilled Syringes Price Curve, 2016-2026 (USD per unit)
  • Figure 13.2 Prefilled Syringes Market for Vaccines, 2016-2026: Base Scenario (Million Units)
  • Figure 13.3 Prefilled Syringes Market for Vaccines, 2016-2026: Base Scenario (USD Million)
  • Figure 13.4 Prefilled Syringes Market for Anticoagulants, 2016-2026: Base Scenario (Million Units)
  • Figure 13.5 Prefilled Syringes Market for Anticoagulants, 2016-2026: Base Scenario (USD Million)
  • Figure 13.6 Prefilled Syringes Market for Anticoagulants, 2016: Distribution by Nature of Molecule (%)
  • Figure 13.7 Prefilled Syringes Market for Diabetes Drugs, 2016-2026: Base Scenario (Million Units)
  • Figure 13.8 Prefilled Syringes Market for Diabetes Drugs, 2016-2026: Base Scenario (USD Million)
  • Figure 13.9 Prefilled Syringes Market for Diabetes Drugs, 2016: Distribution by Nature of Molecule (%)
  • Figure 13.10 Prefilled Syringes Market for Multiple Sclerosis Drugs, 2016-2026: Base Scenario (Million Units)
  • Figure 13.11 Prefilled Syringes Market for Multiple Sclerosis Drugs, 2016-2026: Base Scenario (USD Million)
  • Figure 13.12 Prefilled Syringes Market for Multiple Sclerosis Drugs, 2016 and 2026: Distribution by Nature of Molecule (%)
  • Figure 13.13 Prefilled Syringes Market for Anti-Arthritic Drugs, 2016-2026: Base Scenario (Million Units)
  • Figure 13.14 Prefilled Syringes Market for Anti-Arthritic Drugs, 2016-2026: Base Scenario (USD Million)
  • Figure 13.15 Prefilled Syringes Market for Anti-Arthritic Drugs, 2016 and 2026: Distribution by Nature of Molecule (%)
  • Figure 13.16 Prefilled Syringes Market for Anti-Anemic Drugs, 2016-2026: Base Scenario (Million units)
  • Figure 13.17 Prefilled Syringes Market for Anti-Anemic Drugs, 2016-2026: Base Scenario (USD Million)
  • Figure 13.18 Prefilled Syringes Market for Anti-Anemic Drugs, 2016: Distribution by Nature of Molecule (%)
  • Figure 13.19 Prefilled Syringes Market for Other Drug Classes, 2016-2026: Base Scenario (Million Units)
  • Figure 13.20 Prefilled Syringes Market for Other Drug Classes, 2016-2026: Base Scenario (USD Million)
  • Figure 13.21 Prefilled Syringes Market for Other Drug Classes, 2016 and 2026: Distribution by Nature of Molecule (%)
  • Figure 13.22 Specialty Prefilled Syringes Market, 2016-2026: Base Scenario (Millions Units)
  • Figure 13.23 Specialty Prefilled Syringes Market, 2016-2026: Base Scenario (USD Million)
  • Figure 13.24 Global Prefilled Syringes Market, 2016-2026: Base Scenario (Million Units)
  • Figure 13.25 Global Prefilled Syringes, Units Growth by Category, 2016-2026 (Base Scenario, Million Units)
  • Figure 13.26 Global Prefilled Syringes Market, 2016-2026: Base Scenario (USD Million)
  • Figure 13.27 Global Prefilled Syringes, Sales Growth by Category, 2016-2026 (Base Scenario, USD Million)
  • Figure 13.28 Prefilled Syringes Market: Distribution by Regions, 2016 and 2026 (%)
  • Figure 13.29 North America Prefilled Syringes Market, 2016-2026: Base Scenario (Million Units)
  • Figure 13.30 North America Prefilled Syringes Market, 2016-2026: Base Scenario (USD Million)
  • Figure 13.31 EU Prefilled Syringes Market, 2016-2026: Distribution by Sub-Regions, Base Scenario (Million Units)
  • Figure 13.32 EU Prefilled Syringes Market, 2016-2026: Distribution by Sub-Regions, Base Scenario (USD Million)
  • Figure 13.33 Asia Pacific Prefilled Syringes Market, 2016-2026: Distribution by Sub-Regions, Base Scenario (Million Units)
  • Figure 13.34 Asia Pacific Prefilled Syringes Market, 2016-2026: Distribution by Sub-Regions, Base Scenario (USD Million)
  • Figure 13.35 Latin America Prefilled Syringes Market, 2016 - 2026: Distribution by Sub-Regions, Base Scenario (Million Units)
  • Figure 13.36 Latin America Prefilled Syringes Market, 2016-2026: Distribution by Sub-Regions, Base Scenario (USD Million)
  • Figure 13.37 Middle East and Africa Prefilled Syringes Market, 2016-2026: Distribution by Sub-Regions, Base Scenario (Million Units)
  • Figure 13.38 Middle East and Africa Prefilled Syringes Market, 2016-2026: Distribution by Sub-Regions, Base Scenario (USD Million)
  • Figure 13.39 Prefilled Syringes Market Attractiveness Analysis by Region
  • Figure 13.40 Prefilled Syringes Market, 2016-2026: Distribution by Type of Material, Base Scenario (Million Units)
  • Figure 13.41 Prefilled Syringes Market, 2016-2026: Distribution by Type of Material, Base Scenario (USD Million)
  • Figure 13.42 Prefilled Syringes Market, 2016-2026: Distribution by Nature of Molecule, Base Scenario (Million Units)
  • Figure 13.43 Prefilled Syringes Market, 2016-2026: Distribution by Nature of Molecule, Base Scenario (USD Million)
  • Figure 13.44 Prefilled Syringes Market Attractiveness Analysis by Nature of Molecule
  • Figure 14.1 Bespak Injectables: Autoinjectors
  • Figure 14.2 Bespak Injectables: Syrina™ Autoinjectors
  • Figure 14.3 DALI Medical Devices: Autoinjectors
  • Figure 14.4 Elcam Medical: Products
  • Figure 14.5 Elcam Medical: Flexi-Q Autoinjectors
  • Figure 14.6 Owen Mumford: Cartridge-Based Injection Pens
  • Figure 14.7 Owen Mumford: Autoinjectors
  • Figure 14.8 SHL Medical: Product Portfolio
  • Figure 14.9 SHL Medical: Prefilled Syringe Based Autoinjectors
  • Figure 14.10 SHL Medical: Cartridge Based Autoinjectors
  • Figure 14.11 SHL Medical: Two-Step Autoinjectors
  • Figure 14.12 SHL Medical: Three-Step Autoinjectors
  • Figure 14.13 Union Medico: 45° Autoinjector Portfolio
  • Figure 14.14 Union Medico: Types of 45°/R Autoinjector
  • Figure 14.15 Union Medico: Types of 90° Autoinjectors
  • Figure 14.16 Ypsomed: Cartridge Based Pen injectors
  • Figure 14.17 Ypsomed: Cartridge Based Dual-Chamber Pen injectors
  • Figure 14.18 Ypsomed: Prefilled Syringe or Cartridge Based Autoinjectors
  • Figure 16.1 SWOT Analysis
  • Figure 16.2 Common Medication Errors
  • Figure 16.3 Common Sources of Medication Errors
  • Figure 16.4 Prefilled Syringe Recalls: Distribution by Type of Issue, 2003-2016
  • Figure 17.1 Fill and Finish Service Providers: Distribution by Region
  • Figure 17.2 Prefilled Syringes Market: 2016, 2021 and 2026 (Billion Units)
  • Figure 17.3 Prefilled Syringes Market: 2016, 2021, and 2026 (USD Billion)

List of Figures

  • Table 3.1 Drugs: Shifted from Vials to Prefilled Syringe Systems
  • Table 3.2 Components of Prefilled Syringes
  • Table 3.3 Classification of Prefilled Syringes
  • Table 3.4 Advantages of Glass as Barrel Material
  • Table 3.5 Prefilled Glass Syringe Recalls
  • Table 3.6 Advantages of Plastic Polymers as Barrel Material
  • Table 3.7 Pharmaceutical Filling Lines: Process Flow by Type of Prefilled Syringe
  • Table 3.8 Prefilled Syringe Systems Available in the Market, 2016: A Comparison by Manufacturer
  • Table 3.9 Glass Prefilled Syringes Available in the Market, 2016
  • Table 3.10 Plastic Prefilled Syringes Available in the Market, 2016
  • Table 4.1 Add-On Safety Device Manufacturers
  • Table 4.2 Integrated Prefilled Safety Device Manufacturers
  • Table 5.1 USFDA Centers for Drugs and Device Approval
  • Table 5.2 US: Regulatory Review Timelines
  • Table 5.3 Regulatory Bodies in EU5 Countries
  • Table 5.4 Saudi Arabia: Regulatory Review Timelines
  • Table 6.1 Population above 60 years (Million), 2015, 2030 and 2050
  • Table 6.2 Autoinjector / Pen-injector Systems Approved in 2013-2016
  • Table 6.3 Autoinjectors / Pen-injectors (Using Prefilled Syringes) Available in the Market
  • Table 7.1 Drugs Approved in Prefilled Syringes, 2013-2016
  • Table 7.2 Other Drugs Sold in Prefilled Syringes
  • Table 7.3 Pipeline Drugs Using Prefilled Syringe System
  • Table 7.4 Leading Anti-Rheumatic Drugs
  • Table 7.5 Anti-Rheumatics Drugs Available in Prefilled Syringes
  • Table 7.6 Anti-Rheumatic Drugs Available in Prefilled Format: Patent Expiry and Biosimilar Development
  • Table 7.7 Leading Multiple Sclerosis Drugs
  • Table 7.8 Multiple Sclerosis Drugs Available in Prefilled Syringes
  • Table 7.9 Multiple Sclerosis Drugs Available in Prefilled Format: Patent Expiry and Biosimilar Development
  • Table 7.10 Leading Antiviral Drugs
  • Table 7.11 Antiviral Drugs Available in Prefilled Syringes
  • Table 7.12 Antiviral Drugs Available in Prefilled Format: Patent Expiry and Biosimilar Development
  • Table 7.13 Leading Anticoagulants
  • Table 7.14 Anticoagulants Available in Prefilled Syringes
  • Table 7.15 Anticoagulants Available in Prefilled Format: Patent Expiry and Biosimilars /Generics Development
  • Table 7.16 Leading Vaccines
  • Table 7.17 Vaccines Available in Prefilled Syringes
  • Table 7.18 Leading Diabetes Drugs
  • Table 7.19 Diabetes Drugs Available in Prefilled Insulin Pen
  • Table 7.20 Diabetes Drugs Available in Prefilled Format: Patent Expiry and Biosimilar Development
  • Table 8.1 Marketed Molecules: Most Likely / Likely / Less likely Candidates for Prefilled Syringes
  • Table 8.2 Pipeline Molecules: Most Likely Candidates for Prefilled Syringes
  • Table 8.3 Pipeline Molecules: Likely Candidates for Prefilled Syringes
  • Table 8.4 Pipeline Molecules: Less Likely Candidates for Prefilled Syringes
  • Table 8.5 Vaccines: Likely Candidates for Prefilled Syringes
  • Table 9.1 Key Manufacturers of Prefilled Syringes
  • Table 9.2 West Pharmaceutical Services: Features of Daikyo Crystal Zenith® Prefilled Syringe
  • Table 9.3 Gerresheimer: Features of Gx® Glass Prefilled Syringe
  • Table 9.4 Gerresheimer: Features of ClearJect® Prefilled Syringe
  • Table 9.5 Nuova Ompi: Features of EZ-Fill® Prefilled Syringe
  • Table 9.6 SCHOTT: Features of syriQ® Prefilled Syringe
  • Table 9.7 SCHOTT: Features of syriQ® Injentle Prefilled Syringe
  • Table 9.8 SCHOTT: Features of TopPac® Prefilled Syringe
  • Table 9.9 Vetter Pharma: Manufacturing Facilities
  • Table 9.10 Weigao: Features of WeGo Glass Prefilled Syringe
  • Table 9.11 Roselabs Group: Features of Rose-Fill® Glass Prefilled Syringe
  • Table 9.12 Roselabs Group: Features of Rose-Fill® Plastic Prefilled Syringe
  • Table 9.13 Shandong Zibo: Features of Prefilled Syringes
  • Table 9.14 Taisei Kako: Features of Glass Prefilled Syringes
  • Table 9.15 Taisei Kako: Features of ClearJect®Prefilled Syringes
  • Table 10.1 Prefilled Syringe Component Manufacturers
  • Table 10.2 West Pharmaceutical Services: Plungers
  • Table 10.3 West Pharmaceutical Services: Manufacturing Sites for Prefilled Syringe Components
  • Table 10.4 Datwyler: Plunger Designs
  • Table 10.5 Datwyler: Needle Shields and Tip Caps
  • Table 10.6 Aptar Stelmi: Plungers Designs
  • Table 11.1 Fill-Finish Service Providers for Prefilled syringes
  • Table 11.2 Pfizer CentreOne: Manufacturing Plants
  • Table 11.3 ROVI CM: Manufacturing Plants
  • Table 12.1 Prefilled Flush Syringes Available in the Market
  • Table 12.2 Drugs Available in Prefilled Diluent Syringe System
  • Table 12.3 Contrast Agents Available in Prefilled Syringes
  • Table 13.1 Prefilled Syringes Price Estimate (USD per unit)
  • Table 13.2 Vaccines Administered via Prefilled Syringes
  • Table 13.3 List of Anticoagulants and Mode of Delivery
  • Table 13.4 List of Anticoagulants Sold in Prefilled Syringes
  • Table 13.5 List of Multiple Sclerosis Drugs and Mode of Delivery
  • Table 13.6 List of Multiple Sclerosis Drugs Sold in Prefilled Syringes
  • Table 13.7 List of Anti-Arthritic Drugs and Mode of Delivery
  • Table 13.8 List of Anti-Arthritic Drugs Sold in Prefilled Syringes
  • Table 13.9 List of Anti-Anemic Drugs and Modes of Drug Delivery
  • Table 13.10 List of Anti-Anemic Drugs Sold in Prefilled Syringes
  • Table 13.11 List of Other Drugs Sold in Prefilled Syringes
  • Table 13.12 List of Marketed Drugs in Prefilled Syringes
  • Table 13.13 List of Pipeline Drugs in Prefilled syringes (Phase III and Above)
  • Table 14.1 List of Autoinjector Devices (Using Prefilled Syringes)
  • Table 14.2 Features of Autoject® Flex Variants
  • Table 15.1 Prefilled Syringes for Lyophilized Drugs
  • Table 15.2 Drugs Marketed in Dual / Multi-Chamber Prefilled Syringes
  • Table 16.1 Prefilled Syringe Recalls, 2003-2016
  • Table 16.2 List of Marketed/Pipeline Needleless Injection Devices
  • Table 19.1 Global Prevalence of Diabetes: Distribution by Countries, 2015 (Million, %)
  • Table 19.2 Numbers of Biologics Approved by the USFDA, 2009-2016
  • Table 19.3 Approved Drugs: Therapeutic Area Analysis (2013-2016)
  • Table 19.4 Sales of Leading Drugs Available in Prefilled Syringes, 2016 (USD Million)
  • Table 19.5 HUMIRA®: Global Sales, 2003-Q3 2016 (USD Million)
  • Table 19.6 Enbrel®: Annual Sales in the US and Canada, 2002-2015 (USD Million)
  • Table 19.7 Enbrel®: Annual Sales Outside US and Canada, 2010-2015 (USD Million)
  • Table 19.8 Copaxone ®: Annual Sales, 2001-Q3 2016 (USD Million)
  • Table 19.9 Copaxone ®: Distribution by Vials and Prefilled Syringes, 2000-2008 (Million Units)
  • Table 19.10 Lovenox®: Global Annual Sales, 2009-Q3 2016 (EUR Million)
  • Table 19.11 Number of Approved / Pipeline Biosimilars of Anti-Rheumatics
  • Table 19.12 Number of Approved / Pipeline Biosimilars of Multiple Sclerosis Drugs
  • Table 19.13 Number of Approved / Pipeline Biosimilars of Antivirals
  • Table 19.14 Number of Approved / Pipeline Biosimilars and Generics of Anticoagulants
  • Table 19.15 Number of Approved / Pipeline Biosimilars of Diabetes Drugs
  • Table 19.16 BD Medical: Annual Revenues, 2011-2016 (USD Billion)
  • Table 19.17 BD Medical: Revenue Distribution by Sub-Segments, 2016 (USD Billion)
  • Table 19.18 Unilife Corporation: Annual Revenues, FY 2011/12-2015/16 (USD Million)
  • Table 19.19 West Pharmaceutical Services: Annual Revenues, 2011-Q3 2016 (USD Million)
  • Table 19.20 West Pharmaceutical Services: Revenue Distribution by Business Segments, 2015 (USD Million)
  • Table 19.21 West Pharmaceutical Services: Annual Revenues of Delivery Systems Segment, 2011-2015 (USD Million)
  • Table 19.22 West Pharmaceutical Services: Annual Revenue in the US and Overseas, 2011-2015 (USD Million)
  • Table 19.23 West Pharmaceutical Services: Revenue Distribution by Region, 2015 (USD Million)
  • Table 19.24 Gerresheimer: Annual Revenues, 2011-Q3 2016 (EUR Million)
  • Table 19.25 Gerresheimer: Revenue Distribution by Business Divisions, 2015 (EUR Million)
  • Table 19.26 Gerresheimer: Revenue Distribution by Regions, 2011- 2015 (EUR Million)
  • Table 19.27 SCHOTT: Annual Revenues, FY 2012/13-FY 2014/15 (EUR Million)
  • Table 19.28 SCHOTT: Revenue Distribution by Business Divisions, FY 2014/15 (EUR Million)
  • Table 19.29 SCHOTT: Revenue Distribution by Regions, FY 2014/15 (EUR Million)
  • Table 19.30 Nipro Corporation: Annual Revenues, 2011/12-2015/16 (YEN Billion)
  • Table 19.31 Nipro Corporation: Revenue Distribution by Business Divisions, 2015/16 (YEN Billion)
  • Table 19.32 Nipro Corporation: Revenue Distribution by Regions, 2015/16 (YEN Billion)
  • Table 19.33 Nipro Corporation: Revenue by Regions, 2011/12-2015/16 (YEN Billion)
  • Table 19.34 Weigao: Annual Revenues of Prefilled Syringes, 2011-H1 2016 (RMB Million)
  • Table 19.35 Weigao: Revenue Distribution by Product Category, 2015 (RMB Million)
  • Table 19.36 Terumo Corporation: Annual Revenues, 2011-H1 2016 (YEN Billion)
  • Table 19.37 Terumo Corporation: Revenue Distribution by Business Divisions, FY 2015/16 (YEN Billion)
  • Table 19.38 Terumo Corporation: Revenue Distribution by Region, FY 2015/16 (YEN Billion)
  • Table 19.39 Datwyler Group: Annual Revenues, 2011-H1 2016 (CHF Million)
  • Table 19.40 Datwyler Group: Sales by Business Divisions, 2015 (CHF Million)
  • Table 19.41 Aptar Stelmi: Annual Revenues, 2013-2015 (USD Million)
  • Table 19.42 Prefilled Syringes Price Curve, 2016-2026 (USD per unit)
  • Table 19.43 Prefilled Syringes Market for Vaccines, 2016-2026: Base Scenario (Million Units)
  • Table 19.44 Prefilled Syringes Market for Vaccines, 2016-2026: Optimistic Scenario (Million Units)
  • Table 19.45 Prefilled Syringes Market for Vaccines, 2016-2026: Conservative Scenario (Million Units)
  • Table 19.46 Prefilled Syringes Market for Vaccines, 2016-2026: Base Scenario (USD Million)
  • Table 19.47 Prefilled Syringes Market for Vaccines, 2016-2026: Optimistic Scenario (USD Million)
  • Table 19.48 Prefilled Syringes Market for Vaccines, 2016-2026: Conservative Scenario (USD Million)
  • Table 19.49 Prefilled Syringes Market for Anticoagulants, 2016-2026: Base Scenario (Million Units)
  • Table 19.50 Prefilled Syringes Market for Anticoagulants, 2016-2026: Optimistic Scenario (Million Units)
  • Table 19.51 Prefilled Syringes Market for Anticoagulants, 2016-2026: Conservative Scenario (Million Units)
  • Table 19.52 Prefilled Syringes Market for Anticoagulants, 2016-2026: Base Scenario (USD Million)
  • Table 19.53 Prefilled Syringes Market for Anticoagulants, 2016-2026: Optimistic Scenario (USD Million)
  • Table 19.54 Prefilled Syringes Market for Anticoagulants, 2016-2026: Conservative Scenario (USD Million)
  • Table 19.55 Prefilled Syringes Market for Anticoagulants, 2016: Distribution by Nature of Molecule (%)
  • Table 19.56 Prefilled Syringes Market for Diabetes Drugs, 2016-2026: Base Scenario (Million Units)
  • Table 19.57 Prefilled Syringes Market for Diabetes Drugs, 2016-2026: Optimistic Scenario (Million Units)
  • Table 19.58 Prefilled Syringes Market for Diabetes Drugs, 2016-2026: Conservative Scenario (Million Units)
  • Table 19.59 Prefilled Syringes Market for Diabetes Drugs, 2016-2026: Base Scenario (USD Million)
  • Table 19.60 Prefilled Syringes Market for Diabetes Drugs, 2016-2026: Optimistic Scenario (USD Million)
  • Table 19.61 Prefilled Syringes Market for Diabetes Drugs, 2016-2026: Conservative Scenario (USD Million)
  • Table 19.62 Prefilled Syringes Market for Diabetes Drugs, 2016: Distribution by Nature of Molecule (%)
  • Table 19.62 Prefilled Syringes Market for Multiple Sclerosis Drugs, 2016-2026: Base Scenario (Million Units)
  • Table 19.63 Prefilled Syringes Market for Multiple Sclerosis Drugs, 2016-2026: Optimistic Scenario (Million Units)
  • Table 19.64 Prefilled Syringes Market for Multiple Sclerosis Drugs, 2016-2026: Conservative Scenario (Million Units)
  • Table 19.65 Prefilled Syringes Market for Multiple Sclerosis Drugs, 2016-2026: Base Scenario (USD Million)
  • Table 19.66 Prefilled Syringes Market for Multiple Sclerosis Drugs, 2016-2026: Optimistic Scenario (USD Million)
  • Table 19.67 Prefilled Syringes Market for Multiple Sclerosis Drugs, 2016-2026: Conservative Scenario (USD Million)
  • Table 19.68 Prefilled Syringes Market for Multiple Sclerosis Drugs, 2016 and 2026: Distribution by Nature of Molecule (%)
  • Table 19.69 Prefilled Syringes Market for Anti-Arthritic Drugs, 2016-2026: Base Scenario (Million Units)
  • Table 19.70 Prefilled Syringes Market for Anti-Arthritic Drugs, 2016-2026: Optimistic Scenario (Million Units)
  • Table 19.71 Prefilled Syringes Market for Anti-Arthritic Drugs, 2016-2026: Conservative Scenario (Million Units)
  • Table 19.72 Prefilled Syringes Market for Anti-Arthritic Drugs, 2016-2026: Base Scenario (USD Million)
  • Table 19.73 Prefilled Syringes Market for Anti-Arthritic Drugs, 2016-2026: Optimistic Scenario (USD Million)
  • Table 19.74 Prefilled Syringes Market for Anti-Arthritic Drugs, 2016-2026: Conservative Scenario (USD Million)
  • Table 19.75 Prefilled Syringes Market for Anti-Arthritic Drugs, 2016 and 2026: Distribution by Nature of Molecule (%)
  • Table 19.76 Prefilled Syringes Market for Anti-Anemic Drugs, 2016-2026: Base Scenario (Million Units)
  • Table 19.77 Prefilled Syringes Market for Anti-Anemic Drugs, 2016-2026: Optimistic Scenario (Million Units)
  • Table 19.78 Prefilled Syringes Market for Anti-Anemic Drugs, 2016-2026: Conservative Scenario (Million Units)
  • Table 19.79 Prefilled Syringes Market for Anti-Anemic Drugs, 2016-2026: Base Scenario (USD Million)
  • Table 19.80 Prefilled Syringes Market for Anti-Anemic Drugs, 2016-2026: Optimistic Scenario (USD Million)
  • Table 19.81 Prefilled Syringes Market for Anti-Anemic Drugs, 2016-2026: Conservative Scenario (USD Million)
  • Table 19.82 Prefilled Syringes Market for Anti-Arthritic Drugs, 2016: Distribution by Nature of Molecule (%)
  • Table 19.83 Prefilled Syringes Market for Other Drug Classes, 2016-2026: Base Scenario (Million Units)
  • Table 19.84 Prefilled Syringes Market for Other Drug Classes, 2016-2026: Optimistic Scenario (Million Units)
  • Table 19.85 Prefilled Syringes Market for Other Drug Classes, 2016-2026: Conservative Scenario (Million Units)
  • Table 19.86 Prefilled Syringes Market for Other Drug Classes, 2016-2026: Base Scenario (USD Million)
  • Table 19.87 Prefilled Syringes Market for Other Drug Classes, 2016-2026: Optimistic Scenario (USD Million)
  • Table 19.88 Prefilled Syringes Market for Other Drug Classes, 2016-2026: Conservative Scenario (USD Million)
  • Table 19.89 Prefilled Syringes Market for Other Drug Classes, 2016 and 2026: Distribution by Nature of Molecule (%)
  • Table 19.90 Specialty Prefilled Syringes Market, 2016-2026: Base Scenario (Millions Units)
  • Table 19.91 Specialty Prefilled Syringes Market, 2016-2026: Optimistic Scenario (Millions Units)
  • Table 19.92 Specialty Prefilled Syringes Market, 2016-2026: Conservative Scenario (Millions Units)
  • Table 19.93 Specialty Prefilled Syringes Market, 2016-2026: Base Scenario (USD Million)
  • Table 19.94 Specialty Prefilled Syringes Market, 2016-2026: Optimistic Scenario (USD Million)
  • Table 19.95 Specialty Prefilled Syringes Market, 2016-2026: Conservative Scenario (USD Million)
  • Table 19.96 Global Prefilled Syringes Market, 2016-2026: Base Scenario (Million Units)
  • Table 19.97 Global Prefilled Syringes Market, 2016-2026: Optimistic Scenario (Million Units)
  • Table 19.98 Global Prefilled Syringes Market, 2016-2026: Conservative Scenario (Million Units)
  • Table 19.99 Global Prefilled Syringes, Units Growth by Category, 2016- 026 (Base Scenario, Million Units)
  • Table 19.100 Global Prefilled Syringes, Units Growth by Category, 2016 - 2026 (Optimistic Scenario, Million Units)
  • Table 19.101 Global Prefilled Syringes, Units Growth by Category, 2016 - 2026 (Conservative Scenario, Million Units)
  • Table 19.102 Global Prefilled Syringes Market, 2016-2026: Base Scenario (USD Million)
  • Table 19.103 Global Prefilled Syringes Market, 2016-2026: Optimistic Scenario (USD Million)
  • Table 19.104 Global Prefilled Syringes, Sales Growth by Category, 2016-2026 (Conservative Scenario, USD Million)
  • Table 19.105 Global Prefilled Syringes, Sales Growth by Category, 2016-2026 (Base Scenario, USD Million)
  • Table 19.106 Global Prefilled Syringes, Sales Growth by Category, 2016-2026 (Optimistic Scenario, USD Million)
  • Table 19.107 Global Prefilled Syringes, Sales Growth by Category, 2016 - 2026 (Conservative Scenario, USD Million)
  • Table 19.108 Prefilled Syringe Market: Distribution by Regions, 2016 and 2026 (%)
  • Table 19.109 North America Prefilled Syringe Market, 2016-2026: Base Scenario (Million Units)
  • Table 19.110 North America Prefilled Syringe Market, 2016-2026: Optimistic Scenario (Million Units)
  • Table 19.111 North America Prefilled Syringe Market, 2016-2026: Conservative Scenario (Million Units)
  • Table 19.112 North America Prefilled Syringe Market, 2016-2026: Base Scenario (USD Million)
  • Table 19.113 North America Prefilled Syringe Market, 2016-2026: Optimistic Scenario (USD Million)
  • Table 19.114 North America Prefilled Syringe Market, 2016-2026: Conservative Scenario (USD Million)
  • Table 19.115 EU Prefilled Syringe Market, 2016-2026: Distribution by Sub-Regions, Base Scenario (Million Units)
  • Table 19.116 EU Prefilled Syringe Market, 2016-2026: Distribution by Sub-Regions, Optimistic Scenario (Million Units)
  • Table 19.117 EU Prefilled Syringe Market, 2016-2026: Distribution by Sub-Regions, Conservative Scenario (Million Units)
  • Table 19.118 EU Prefilled Syringe Market, 2016-2026: Base Scenario (USD Million)
  • Table 19.119 EU Prefilled Syringe Market, 2016-2026: Optimistic Scenario (USD Million)
  • Table 19.120 EU Prefilled Syringe Market, 2016-2026: Conservative Scenario (USD Million)
  • Table 19.121 Asia Pacific Prefilled Syringe Market, 2016-2026: Distribution by Sub-Regions, Base Scenario (Million Units)
  • Table 19.122 Asia Pacific Prefilled Syringe Market, 2016-2026: Distribution by Sub-Regions, Optimistic Scenario (Million Units)
  • Table 19.123 Asia Pacific Prefilled Syringe Market, 2016-2026: Distribution by Sub-Regions, Conservative Scenario (Million Units)
  • Table 19.124 Asia Pacific Prefilled Syringe Market, 2016-2026: Base Scenario (USD Million)
  • Table 19.125 Asia Pacific Prefilled Syringe Market, 2016-2026: Optimistic Scenario (USD Million)
  • Table 19.126 Asia Pacific Prefilled Syringe Market, 2016-2026: Conservative Scenario (USD Million)
  • Table 19.127 Latin America Prefilled Syringe Market, 2016-2026: Distribution by Sub-Regions, Base Scenario (Million Units)
  • Table 19.128 Latin America Prefilled Syringe Market, 2016-2026: Distribution by Sub-Regions, Optimistic Scenario (Million Units)
  • Table 19.129 Latin America Prefilled Syringe Market, 2016-2026: Distribution by Sub-Regions, Conservative Scenario (Million Units)
  • Table 19.130 Latin America Prefilled Syringe Market, 2016-2026: Base Scenario (USD Million)
  • Table 19.131 Latin America Prefilled Syringe Market, 2016-2026: Optimistic Scenario (USD Million)
  • Table 19.132 Latin America Prefilled Syringe Market, 2016-2026: Conservative Scenario (USD Million)
  • Table 19.133 Middle East and Africa Prefilled Syringe Market, 2016-2026: Distribution by Sub-Regions, Base Scenario (Million Units)
  • Table 19.134 Middle East and Africa Prefilled Syringe Market, 2016-2026: Distribution by Sub-Regions, Optimistic Scenario (Million Units)
  • Table 19.135 Middle East and Africa Prefilled Syringe Market, 2016-2026: Distribution by Sub-Regions, Conservative Scenario (Million Units)
  • Table 19.136 Middle East and Africa Prefilled Syringe Market, 2016-2026: Base Scenario (USD Million)
  • Table 19.137 Middle East and Africa Prefilled Syringe Market, 2016-2026: Optimistic Scenario (USD Million)
  • Table 19.138 Middle East and Africa Prefilled Syringe Market, 2016-2026: Conservative Scenario (USD Million)
  • Table 19.139 Prefilled Syringe Market Attractiveness Analysis by Region
  • Table 19.140 Prefilled Syringe Market, 2016-2026: Distribution by Type of Material, Base Scenario (Million Units)
  • Table 19.141 Prefilled Syringe Market, 2016-2026: Distribution by Type of Material, Optimistic Scenario (Million Units)
  • Table 19.142 Prefilled Syringe Market, 2016-2026: Distribution by Type of Material, Conservative Scenario (Million Units)
  • Table 19.143 Prefilled Syringe Market, 2016-2026: Distribution by Type of Material, Base Scenario (USD Million)
  • Table 19.144 Prefilled Syringe Market, 2016-2026: Distribution by Type of Material, Optimistic Scenario (USD Million)
  • Table 19.145 Prefilled Syringe Market, 2016-2026: Distribution by Type of Material, Conservative Scenario (USD Million)
  • Table 19.146 Prefilled Syringe Market, 2016-2026: Distribution by Nature of Molecule, Base Scenario (Million Units)
  • Table 19.147 Prefilled Syringe Market, 2016-2026: Distribution by Nature of Molecule, Optimistic Scenario (Million Units)
  • Table 19.148 Prefilled Syringe Market, 2016-2026: Distribution by Nature of Molecule, Conservative Scenario (Million Units)
  • Table 19.149 Prefilled Syringe Market, 2016-2026: Distribution by Nature of Molecule, Base Scenario (USD Million)
  • Table 19.150 Prefilled Syringe Market, 2016-2026: Distribution by Nature of Molecule, Optimistic Scenario (USD Million)
  • Table 19.151 Prefilled Syringe Market, 2016-2026: Distribution by Nature of Molecule, Conservative Scenario (USD Million)
  • Table 19.152 Prefilled Syringe Market Attractiveness Analysis by Nature of Molecules
  • Table 19.153 Common Medication Errors
  • Table 19.154 Common Sources of Medication Errors
  • Table 19.155 Prefilled Syringe Recalls: Distribution by Type of Issue, 2003-2016
  • Table 19.156 Prefilled Syringes Market: 2016, 2021 and 2026 (Billion Units)
  • Table 19.157 Prefilled Syringes Market: 2016, 2021, and 2026 (USD Billion)

Listed Companies

The following companies have been mentioned in the report.

  • 1. 3SBio
  • 2. Abbott
  • 3. AbbVie Biotherapeutics
  • 4. AbbVie Contract Manufacturing
  • 5. Ablynx
  • 6. Acceleron Pharma
  • 7. Accord Healthcare
  • 8. AC Immune
  • 9. Activa Brand Products
  • 10. Adamis Pharmaceuticals Corporation
  • 11. Advanced Medical Systems
  • 12. AET BioTech
  • 13. Aeras
  • 14. Agila Biotech
  • 15. Aguettant
  • 16. AJ Biologics
  • 17. Ajinomoto Althea
  • 18. Akcea Therapeutics
  • 19. Akorn
  • 20. Aldagen
  • 21. Alkermes
  • 22. Alteogen
  • 23. Adocia
  • 24. Alchemia
  • 25. Alder BioPharmaceuticals
  • 26. Alfamatic
  • 27. Allergan
  • 28. Allergy Therapeutics
  • 29. Allozyne
  • 30. Alkermes
  • 31. Almirall
  • 32. Alvogen
  • 33. AMEGA Biotech
  • 34. Amgen
  • 35. Amphastar Pharmaceuticals
  • 36. AnGes
  • 37. Antares Pharma
  • 38. Anthera Pharmaceuticals
  • 39. AOP Orphan Pharmaceuticals
  • 40. Apellis Pharmaceuticals
  • 41. APL Pharma
  • 42. Aptar Stelmi
  • 43. Apobiologix
  • 44. Apotex
  • 45. Aquabiliti
  • 46. Araim Pharmaceuticals
  • 47. Argenx
  • 48. Ariston
  • 49. Arte Corporation
  • 50. AryoGen
  • 51. Aspen Group
  • 52. Astellas Pharma
  • 53. AstraZeneca
  • 54. Aurum Pharmaceuticals
  • 55. Avesthagen
  • 56. AXXO
  • 57. Bahrain Pharma
  • 58. Bang and Olufsen
  • 59. BASF Bioresearch Corporation
  • 60. Bavarian Nordic
  • 61. Baxter
  • 62. Bayer Healthcare
  • 63. B. Braun Medical
  • 64. Beacon Pharmaceuticals
  • 65. Becton Dickinson
  • 66. Bespak
  • 67. Bharat Serums & Vaccines
  • 68. BIOCAD
  • 69. Biocon
  • 70. BioConnection
  • 71. Bio Farma
  • 72. Biodel
  • 73. Bio Elpida
  • 74. BioGenomics
  • 75. BioIncept
  • 76. Bioject Medical Technologies
  • 77. BioMarin Pharmaceutical
  • 78. Bioneer
  • 79. BioPharma Solutions
  • 80. Biosidus
  • 81. Biotechpharma
  • 82. Biotech Visioncare
  • 83. Bioviz Technologies
  • 84. BioXpress Therapeutics
  • 85. Blausiegel
  • 86. Blau Farmacêutica
  • 87. Boehringer Ingelheim BioXcellence
  • 88. Bone Therapeutics
  • 89. Boryung Pharmaceutical
  • 90. Bracco Diagnostics
  • 91. Braeburn Pharmaceuticals
  • 92. BrainStorm Cell Therapeutics
  • 93. Bristol Myers Squibb
  • 94. Bryllan
  • 95. Buender Glas
  • 96. Cadila Healthcare
  • 97. Cambridge Antibody Technology
  • 98. Cambridge Consultants
  • 99. Camurus
  • 100. Canyon Pharmaceuticals
  • 101. Capricor Therapeutics
  • 102. Cardinal Health
  • 103. Central Admixture Pharmacy Services
  • 104. Catalent Pharma Solutions
  • 105. CCM Pharmaceuticals
  • 106. Celgene
  • 107. Cellofarm
  • 108. Celltrion
  • 109. Cenexi
  • 110. Chandra Bhagat Pharma
  • 111. Chugai Pharmaceutical
  • 112. CinnaGen
  • 113. Cipla
  • 114. Cipla BioTec
  • 115. Cobra Biologics
  • 116. Coherus Biosciences
  • 117. Consort Medical
  • 118. Cook Pharmica
  • 119. Corden Pharma
  • 120. Covidien
  • 121. CP Guojian Pharmaceutical
  • 122. CROSSJECT
  • 123. Cytheris
  • 124. CytoDyn
  • 125. Cytori Therapeutics
  • 126. Credence MedSystems
  • 127. Crealta Pharmaceuticals
  • 128. CSL Biotherapies
  • 129. Daewoong Pharmaceutical
  • 130. Daicel Corporation
  • 131. Daiichi Sankyo
  • 132. Daikyo Seiko
  • 133. DALI Medical Devices
  • 134. Datwyler
  • 135. Dermira
  • 136. Diasome Pharmaceuticals
  • 137. Diamyd Medical
  • 138. DM Bio
  • 139. Dong-A Pharmaceutical
  • 140. Dr. Lazar Laboratorio
  • 141. Dr. Reddy's Laboratories
  • 142. Dynavax Technologies Corporation
  • 143. Eisai
  • 144. Elan Corporation
  • 145. Elcam Medical
  • 146. Eli Lilly
  • 147. Emcure Pharmaceuticals
  • 148. EMD Serono
  • 149. Emergent BioSolutions
  • 150. Enzon Pharmaceuticals
  • 151. Eternity Healthcare
  • 152. European Medical Contract Manufacturing
  • 153. Eurofarma
  • 154. Evans Enterprises
  • 155. EVER Pharma
  • 156. Excelsior Medical
  • 157. Exsulin
  • 158. Eyetech
  • 159. Farmabion Del Ecuador
  • 160. Ferring Pharmaceuticals
  • 161. Finox Biotech
  • 162. Flamel Technologies
  • 163. Fresenius Kabi
  • 164. Fujifilm Kyowa Kirin Biologics
  • 165. Future Injection Technologies
  • 166. Gan & Lee Pharmaceutical
  • 167. Gedeon Richter
  • 168. GE Healthcare
  • 169. Genentech
  • 170. GeneOne Life Sciences
  • 171. Gene Techno Science
  • 172. Genovior Biotech
  • 173. Generon (Shanghai) Corporation
  • 174. Genocea Biosciences
  • 175. Genzyme Corporation
  • 176. GeoVax
  • 177. Gerresheimer
  • 178. GeroPharm
  • 179. Gerot Lannach Pharma
  • 180. Gilead Sciences
  • 181. Gland Pharma
  • 182. GlaxoSmithKline
  • 183. GlobeImmune
  • 184. Globe Medical Tech
  • 185. Green Cross Corporation
  • 186. Guerbet
  • 187. Halozyme Therapeutics
  • 188. HanAll Biopharma
  • 189. Hanmi Pharmaceutical
  • 190. Hanwha Chemical
  • 191. Harvest Moon Pharmaceuticals
  • 192. Haselmeier
  • 193. Health for personal care corporation
  • 194. Helocyte
  • 195. Helvoet Pharmaceutical
  • 196. Hemispherx Bioscience
  • 197. Heron Therapeutics
  • 198. Hikma Pharmaceuticals
  • 199. Hospira
  • 200. Horizon Pharma
  • 201. Hyaluron Contract Manufacturing
  • 202. Ichor Medical Systems
  • 203. ID Biomedical Corporation of Quebec
  • 204. Idera Pharmaceutical
  • 205. Il-Yang Pharm
  • 206. Immunex Corporation
  • 207. Immunomedics
  • 208. Immune Response BioPharma
  • 209. Incepta Pharmaceuticals
  • 210. Indivior
  • 211. Infusive Technologies
  • 212. Injex
  • 213. Inovio Pharmaceuticals
  • 214. Innovate UK
  • 215. Intas Pharmaceuticals
  • 216. Intarcia Therapeutics
  • 217. Integrated BioTherapeutics
  • 218. Integrity Bio
  • 219. Ionis Pharmaceuticals
  • 220. Ipsen
  • 221. Italfarmaco
  • 222. IVEK Corporation
  • 223. Johnson & Johnson
  • 224. J.O. Pharma
  • 225. JSR Corporation
  • 226. JCR Pharmaceuticals
  • 227. JMS
  • 228. JN-International Medical Corporation
  • 229. Juventas Therapeutics
  • 230. Kaleo
  • 231. Kastle Therapeutics
  • 232. Kendall
  • 233. Kineta
  • 234. Kitasato Daiichi Sankyo Vaccine
  • 235. Kyowa Hakko Kirin
  • 236. Laboratorios SALVAT
  • 237. Landec Corporation
  • 238. Landsteiner Laboratories
  • 239. LEO Pharma
  • 240. LG Life Sciences
  • 241. Liebmann Group
  • 242. Lifecore Biomedical
  • 243. Lundbeck
  • 244. Lupin Pharmaceuticals
  • 245. LyoGo
  • 246. Mada Equipment
  • 247. Mallinckrodt
  • 248. Marathon Pharmaceuticals
  • 249. Maruishi Pharmaceutical
  • 250. Medac Pharma
  • 251. Medefil
  • 252. Medex
  • 253. Medicago
  • 254. MedicalChain International Corporation
  • 255. Medical Glass
  • 256. MedImmune
  • 257. Medimop Medical Projects
  • 258. MedPro Safety Products
  • 259. Medtronic
  • 260. MedXL
  • 261. Meiji Seika Pharma
  • 262. Merck
  • 263. Meridian Medical Technologies
  • 264. Merz Pharma
  • 265. MGlas
  • 266. Minapharm Pharmaceuticals
  • 267. Mitsubishi Tanabe
  • 268. Mitsui Chemicals
  • 269. Mitsubishi Gas Chemical
  • 270. MJ Biopharm
  • 271. Mochida Pharmaceuticals
  • 272. Momenta Pharmaceuticals
  • 273. Mycenax Biotech
  • 274. Mylan Institutional
  • 275. Nanogen Biopharmaceutical
  • 276. Nanotherapeutics
  • 277. NATCO Pharma
  • 278. National Medical Products
  • 279. Nektar Therapeutics
  • 280. Nemera
  • 281. Neon Laboratories
  • 282. Neutral Glass & Allied industries
  • 283. Nippon Organon
  • 284. Nipro Corporation
  • 285. Nora Therapeutics
  • 286. Novartis
  • 287. Novalek Pharmaceuticals
  • 288. Nova Laboratories
  • 289. NovaDigm Therapeutics
  • 290. Novavax
  • 291. Novo Nordisk
  • 292. Noxilizer
  • 293. NPS Pharmaceuticals
  • 294. Nuance Designs
  • 295. Nuova Ompi
  • 296. Nuron Biotech
  • 297. Nurse Assist
  • 298. Okairos
  • 299. Omnikron Group
  • 300. Oncobiologics
  • 301. Ono Pharmaceutical
  • 302. Opexa Therapeutics
  • 303. OPKO Biologics
  • 304. Optimum Medical
  • 305. OrbiMed
  • 306. Otsuka Holdings
  • 307. Oval Medical Technologies
  • 308. Owen Mumford
  • 309. PA Consulting
  • 310. Palatin Technologies
  • 311. PANPHARMA
  • 312. Paras Biopharmaceuticals
  • 313. Pars No Tarkib
  • 314. PenJect
  • 315. Pfenex
  • 316. Pfizer
  • 317. Pfizer CentreOne
  • 318. PharmaEssentia Corporation
  • 319. Pharmicell
  • 320. Pharmathen
  • 321. PhaseBio Pharmaceuticals
  • 322. PiSA Farmaceutica
  • 323. Plas-Tech Engineering
  • 324. Pluristem Therapeutics
  • 325. Polpharma
  • 326. Polyplastics
  • 327. PROBIOMED
  • 328. Profectus BioSciences
  • 329. ProJect Pharmaceutics
  • 330. Protalix BioTherapeutics
  • 331. Protein Sciences Corporation
  • 332. PT Bio Farma
  • 333. PYRAMID Laboratories
  • 334. Radius Health
  • 335. Ranbaxy Laboratories
  • 336. Regeneron Pharmaceuticals
  • 337. Reliance Life Sciences
  • 338. REMD Biotherapeutics
  • 339. Retractable Technologies
  • 340. Revolutions Medical Corporation
  • 341. Rexam Pharma
  • 342. Rhône Poulenc-Rorer
  • 343. Rheim Minapharm
  • 344. Rhythm Pharmaceuticals
  • 345. Rompharm Company
  • 346. Roselabs Bioscience
  • 347. Rovi CM
  • 348. SafeShot Technologies
  • 349. Safety Syringes
  • 350. Samsung Bioepsis
  • 351. Sandoz
  • 352. Sanofi Aventis
  • 353. Sanofi Pasteur
  • 354. Santarus
  • 355. Schering-Plough
  • 356. Schreiner MediPharm
  • 357. SCHOTT
  • 358. SHOTT KAISHA
  • 359. Sciele Pharma
  • 360. Seqirus
  • 361. Shandong Pharmaceutical Glass
  • 362. Shandong Weigao Group Medical Polymer Company
  • 363. Shandong Zibo Minkang Pharmaceutical Packing
  • 364. Shanghai Celgen Bio-Pharmaceutical
  • 365. Shantha Biotech
  • 366. Shin Yan Sheno Precision Industrial
  • 367. Shire
  • 368. SHL Medical
  • 369. SiO2 Medical Products
  • 370. Sobi
  • 371. Soligenix
  • 372. Solvay Pharmaceuticals
  • 373. SOVEREIGN PHARMA
  • 374. Spectrum Pharmaceuticals
  • 375. STADA Arzneimittel
  • 376. Stevanato Group
  • 377. Stiefel
  • 378. Strides
  • 379. Sumagen
  • 380. Sun Pharmaceutical Industries
  • 381. Sunshine Health Products
  • 382. Suzuken
  • 383. Swissfillon
  • 384. TaiMed Biologics
  • 385. Taisei Kako
  • 386. Taiyo Yakuhin
  • 387. Taj Pharmaceuticals
  • 388. Takeda Pharmaceutical
  • 389. Talecris Biotherapeutics
  • 390. Techno Pharm
  • 391. Techdow Pharmaceuticals
  • 392. Teijin Pharma
  • 393. Terumo Corporation
  • 394. Teva Pharmaceuticals
  • 395. The Birgi Mefar Group
  • 396. The Medical House
  • 397. The Medicines Company
  • 398. Therapure Biopharma
  • 399. The Tech Group
  • 400. Ticona
  • 401. Tip-Top
  • 402. TOLMAR
  • 403. TriboFilm Research
  • 404. Triveni Polymers
  • 405. Troikaa Pharmaceuticals
  • 406. TSH Biopharm Corporation
  • 407. Tyfill Pharmapack
  • 408. UCB
  • 409. Unicep
  • 410. Unilife Corporation
  • 411. Unimed del Perú
  • 412. Union Medico
  • 413. United Neuroscience
  • 414. United Therapeutics
  • 415. U.S. Medical Instruments
  • 416. Valeant Pharmaceutical International
  • 417. Valeritas
  • 418. Vedat
  • 419. Vaneva
  • 420. VaxInnate
  • 421. Versartis
  • 422. Vetter Pharma
  • 423. ViaCyte
  • 424. Vical
  • 425. Vitaeris
  • 426. Virchow Biotech
  • 427. Viropro
  • 428. ViroMed
  • 429. Watson Pharma
  • 430. WestCon Medical Industries
  • 431. West Pharmaceutical Services
  • 432. Weigao Group Pharmaceutical Packaging Products
  • 433. Wockhardt
  • 434. Wyeth
  • 435. XBiotech
  • 436. Xbrane Biopharma
  • 437. XOMA
  • 438. YangZhong Wealth Metal
  • 439. Youlyy Industrial
  • 440. Ypsomed Delivery Systems
  • 441. Zealand Pharma
  • 442. Zeon Chemicals
  • 443. Zensun
  • 444. Zhejiang Hisun Pharmaceutical
  • 445. Zhejiang Huahai Pharmaceutical
  • 446. Zhejiang Xinkang Pharmaceutical Glass
  • 447. Zogenix
  • 448. Zydus Cadila
  • 449. ZymoGenetics
Back to Top